International PhD Program in Neuroscience
XXIX Cycle

Coordinator: Prof. Salvatore Salomone

miRNA EXPRESSION PROFILES IN RETINAL NEURODEGENERATIVE DISEASES

PhD thesis

Giovanni Luca Romano

Tutor: Prof. Claudio Bucolo

BIOMETEC

Department of Biomedical and Biotechnological Sciences

Section of Pharmacology.

Medical School - University of Catania

2016

TABLE OF CONTENTS

ACKNOWLEDGEMENTS

LIST OF ABBREVIATIONS

Aβ	amyloid β
AD	Alzheimer's disease
ALS	amyotrophic lateral sclerosis
AMD	Age-Related Macular Degeneration
APP	amyloid precursor protein
ARNT	aryl hydrocarbon receptor nuclear translocators
ATPase	Adenosine Triphosphate Phosphatase
ATP	Adenosine Triphosphate
ADP	Adenosine Diphosphate
BACE1	β-secretase
BBB	Blood Brain Barrier
BDNF	Brain-derived neurotrophic factor
BM	Bruch's membrane
BRB	Blood Retinal Barrier
CC	chemokine
CDS	coding sequences
CK/CK-R	cytokine/cytokine-receptor
CNS	central nervous system
CNV	choroidal neovascularization
DAMPs	damage-associated molecular patterns
FC	Fold-changes
GCL	ganglion cell layer
HIF	hypoxia-inducible transcription factor
HMDD	Human miRNA Disease Database
INL	inner nuclear layer
IPL	inner plexiform layer
IVT	intravitreal injection
IOP	intraocular pression
JNK	Jun N-terminal kinase
KO	knockout
miRNAs	microRNAs
mRNAs	messenger RNAs
NF-kB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NFL	nerve fiber layer
NFTs	neurofibrillary tangles;
NGF	Nerve growth factor
NT	Neurotrophins
OCT	Optical coherence tomography
ONH	optic nerve head
ONL	outer nuclear layer

OPL	outer plexiform layer
PD	Parkinson disease
PEDF	pigmented-epithelium-derived-factor
PIGF	placental growth factor
p-tau	phosphorilated tau
RGCs	retinal ganglion cells
RISC	RNA-induced silencing complex
RPE	retinal pigment epithelium
TFs	transcription factors
TFBSs	transcription factors binding sites
TLRs	Toll-like receptors
Trk	tyrosine kinase
VEGF	vascular endothelial growth factor
VEGFRs	VEGF receptors
3'-UTRs	3'-untranslated regions

ABSTRACT

MicroRNAs (miRNAs) are non-coding small RNAs, which have been found to regulate gene expression at the post-transcriptional and translational levels. A lot of studies demonstrated that miRNAs regulate various cellular processes, including differentiation, development, aging, apoptosis, oncogenesis and metabolism. Moreover, dysregulation of specific miRNAs is associated with a variety of diseases, including neurodegenerative disorders. Identification of differenzial pattern expression of miRNAs could be of value for development of novel biomarkers and discovery of new pharmacological targets for human diseases.

The aim of our research was to investigate miRNAs regulation in neurodegenerative diseases. Glaucoma is a progressive optic neuropathy and it is one of the leading cause of blindness in the industrialized countries. Age related macular degeneration (AMD) is the leading cause of blindness among people aged 50 and over. Signs of irreversible neurodegeneration in glaucoma, AMD and Alzheimer's disease (AD), are usually evident at least a decade after onset of disease; thus early diagnosis is an urgent need in order to start effective therapy against neurodegenerative process. Identification of deregulated miRNA and associated pathways common to glaucoma, AMD and AD might help in the challenging search of biomarkers and novel therapeutic strategies.

We found, from literature search, 8 deregulated miRNAs in glaucoma, 9 and 23 in AMD and AD, respectively. One miRNA was found to be commonly deregulated in glaucoma and AMD (miR-23a), two miRNA (miR-29a, miR-29b) in glaucoma and AD, and four miRNAs in AMD and AD (miR-9, miR-31, miR-21, miR-34a, miR-146a). Predicted miRNAs common to the three neurodegenerative diseases were 9 (miR-107, miR-137, miR-146a, miR-181c, miR-197, miR-21, miR-22, miR-590, miR-9), which demonstrate to be involved in the regulation of inflammation pathways. Based on prediction of miRNA and associated biochemical pathways, inflammation could represent a therapeutic target common to glaucoma, AMD and AD.

Then we evaluated the differential expression profile of miRNAs in a rat model of AMD and in patients with AMD. Analysis of rat retina revealed that miR-27a, miR-146a and miR-155 are up-regulated in comparison to control rats. Seven miRNA (miR-9, miR-23a,

miR-27a, miR-34a, miR-126, miR-146a and miR-155) have been found to be dysregulated in serum of AMD patients in comparison to control group. Dysregulated miRNAs, both in the AMD animal model and in AMD patients, can target genes regulating pathways linked to neurodegeneration and inflammation.

Our findings support the assessment of specific miRNAs as potential biomarkers and therapeutic targets in retinal neurodegenerative diseases by means of preclinical and clinical studies.

RETINAL NEURODEGENERATIVE DISEASES

The retina is part of the central nervous system (CNS) due to its neuroectodermal origin and derivation from the anterior neural tube. Figure 1 shows a schematic representation of the major retinal cell types and their organization in the retina. The outer layer is the retinal pigment epithelium (RPE), a monolayer of cuboid, pigmented cells between the photoreceptors and the choroid. The retina is then constituted by three laminar layers: the outer nuclear layer (ONL) that contains cell bodies of photoreceptors; the inner nuclear layer (INL) formed by cell bodies of the bipolar, horizontal, and amacrine cells; the ganglion cell layer (GCL) composed by nuclei of retinal ganglion cells (RGCs) and of displaced amacrine cells. Axons of RGCs form the nerve fiber layer (NFL), beneath the GCL. These cells are interconnected through synapses that occur in the outer and inner plexiform layers (1).

Neurodegeneration describes the slow and progressive dysfunction and loss of neurons or their axons in the CNS. Retinal degenerative diseases, such as glaucoma and age-related macular degeneration (AMD) are chronic neurodegenerative conditions that affect various retinal neurons and lead to progressive and irreversible loss of the vision.

The pathological features of these retinal disorders have been commonly compared to that of the neurodegenerative condition Alzheimer's disease (AD) (Table 1). Although these diseases have very different symptoms, they may result from similar mechanisms.

Age is a risk factor common to glaucoma/AMD of the eye and AD of the brain. (2).

AD progressively impairs brain structures and consequently cognitive ability and is characterized by enhanced amyloid β (Aβ) levels and its deposition in the central nervous system (CNS) (3).

Several human and animal studies reported ocular changes in AD and pathological accumulation of Aβ in the retina (4, 5). Aβ (Figure 2), a peptide of 39-43 amino acids, is the main constituent of senile amyloid plaques in the brains of AD patients and is also deposited in the drusen of eyes with AMD. Interestingly, Aβ and phosphorilated tau (p-tau), have been detected also in glaucoma patients and have a role in retinal ganglion cells (RGCs) death and progression of visual loss.

Therefore, retinal Aβ accumulation can be regarded as a common feature of these three distinct disorders.

Secreted Aβ exists mainly in two isoforms, Aβ 1-40 and Aβ 1-42 forms. Monomers of Aβ1-40 are prevalent in the brain than the Aβ1-42 form. Small amounts of Aβ is deposited

in the normal brain (6) and in the normal retina, and the levels of these deposits increase with increasing age.

Aβ spontaneously aggregates into multiple coexisting physical forms which may have differential neurotoxicity. One form consists of 2-6 peptide oligomers, which combine into intermediate aggregates. Soluble oligomers and intermediate amyloids are considered the most neurotoxic forms of Aβ (7). Moreover, Aβ fibrils can arrange themselves into β-pleated sheets to form insoluble fibres of advanced amyloid plaques.

Aβ deposition induces different effect in cell types involved, resulting in vascular dysfunction, inflammation, oxidative stress and neurotrophin impairment (Figure 3).

The major cell types affected in the brain are neural cells and microglia: Aβ activates microglial cells and causes neuronal cell death.

The major retinal cell type affected by Aβ is retinal pigment epithelium (RPE) cells. Kurji et al. (8) examined changes in gene expression of RPE cells stimulated with Aβ1-40 and found up-regulation of genes of inflammatory and immune response categories, in particular, IL-1β and IL-8, known as angiogenesis molecules. These findings suggest that Aβ triggers inflammatory and angiogenic responses in the RPE/choroidal layers, resulting in the development of choroidal neovascularization (CNV) in wet type of AMD.

Abnormal APP metabolism and increased Aβ expression in RGCs has been associated with the development of RGC apoptosis in experimental models of glaucoma (9).

A greater understanding of the link between these disorders will help in the identification of overlapping molecular mechanisms as well as development of novel and effective treatment strategies.

Characteristic	AD	Glaucoma	AMD
Location of retinal damage	RGC, NFL	RGC, NFL, ONH	RPE, photoreceptors
Aβ deposition	Main component of senile plaques	Reported in RGCs following ocular hypertension	Component of subretinal drusen
pTau	Component of NFTs	Found in inner retina, vitreous, and ONH	Not reported in association with drusen
Oxidative and metabolic stress	Associated with metal deficiencies and neuronal damage	Associated with metabolic strain on RGCs	Associated with visual cycle and drusen formation
Glial reactivity	Astrocytes and microglia around senile plaques	Astrocytes and microglia in NFL, peripapillary space, and ONH	Microglia in subretinal space and around drusen
Genetic linkage	No clear commonalities, though there may be a mild association between distinct APOE alleles for AD and AMD		

Table 1: Similarities and Differences between AD, Glaucoma, and AMD.
NFL: nerve fiber layer; NFTs: neurofibrillary tangles; ONH: optic nerve head; pTau: hyperphosphorylated tau protein; RGC: retinal ganglion cell; RPE: retinal pigmented epithelium.

Figure 1: Schematic representation of the major retinal cell types and their organization in the retina. RPE: retinal pigment epithelium; ONL: outer nuclear layer; INL: inner nuclear layer; GCL: ganglion cell layer; NFL nerve fiber layer; OPL: outer plexiform layer; IPL: inner plexiform layer.

Figure 2: The amyloid cascade and major therapeutic approaches targeting amyloid β (Aβ) (K. Ohno-Matsui. Progress in Retinal and Eye Research. 2011). The transmembrane amyloid precursor protein (APP) is sequentially cleaved by two proteases, β-secretase (BACE1) and γ-secretase, to release various isoforms of the Aβ peptide. The fragment Aβ1-42 aggregates to form toxic oligomers and is deposited in amyloid plaques. A major therapeutic effort is aimed at reducing Aβ1-42 production with BACE1-inhibitors and with γ-secretase inhibitors and modulators. Another therapeutic approach aims to enhance the clearance of Aβ, with antibodies or vaccines directed at soluble monomeric Aβ and/or oligomers and/or plaques.

Figure 3: impact of Aβ on the visual structure and function in AD, AMD and glaucoma (V. Gupta et al. Cell. Mol. Life Sci. (2016) 73:4279–4297).

Glaucoma is a progressive optic neuropathy that involve optic disc degeneration and visual field aberration. It is one of the leading cause of blindness in the industrialized countries.

It has been described as an "*optic vasobaropathy*" indicating that both vascular and mechanical pressure processes contribute to the optic nerve damage (27). Besides high intraocular pressure (IOP), aging is one of the mainly recognized risk factor of glaucoma, and it has been proposed to have a neurodegenerative imprint.

The relative increase in IOP is related to an imbalance between aqueous humor (AH) production (by the ciliary body) and drainage (through the trabecular meshwork and Schlemm's canal).

Glaucoma is principally divided into open-angle and angle-closure subtypes. Angle closure is characterized by an obstruction of the trabecular meshwork and elevated IOP.

The most common form of glaucoma is the primary open angle glaucoma (POAG) associated to increased intraocular pression (IOP). However, there are about 20-52% of glaucomatous patients with normal IOP and those patients develop damage at the optic nerve head similar to POAG patients. Ocular hypertension (> 21 mmHg) can arise asymptomatically and patients develop symptomatic visual field loss when damage is irreversible.

Both open-angle glaucoma and angle-closure glaucoma can be further subdivided into primary or secondary diseases, where primary refers to forms not correlated to previous and concomitant ocular disease (28). Secondary gluacoma refers to an elevated IOP with an identifiable pathological cause, such as inflammation, trauma, neovascularisation or iatrogenic causes.

Age-dependent accumulation of Aβ in RGCs has been suggested to contribute to glaucoma pathology. Human post-mortem and animal studies have found aggregation of Aβ and other proteins in the retina exposed to increased IOP which then promotes RGC apoptosis.

Diagnostic evaluation

The diagnosis of glaucoma is achieved using functional and structural assessments. The standard automated perimetry (SAP) is considered the gold standard for visual field assessment and monitoring of visual field loss. Structural diagnostic tools are principally based on the quantification of retinal nerve fibre layer (RNFL) thickness changes by optical

coherence tomography (OCT) and disc tomography (confocal laser-scanning tomography, cSLO) to assess changes of the optic nerve head (ONH).

IOP is assessed using tonometry devices, and the gold standard remain Goldman applanation tonometry (GAT).

Pharmacological treatments of glaucoma

Up to know the only therapeutic approach in glaucoma therapy is aimed at decreasing the IOP, also in normotensive glaucomatous patients. Reducing the baseline IOP by at least 20% generally will prevent progression of visual field loss, even in patients with IOP within the normal range (29-37).

AH inflow and outflow facilities are the pharmacological targets of ocular hypotensive drugs.

The canonical treatment remains the topical use of β receptor antagonists or prostaglandin analogues. Common alternate treatment modalities include carbonic anhydrase inhibitors or α2 adrenergic agonists.

Beta-blockers antagonizes β-adrenergic receptors of iris-ciliary body system inhibiting AH production. Several beta-blockers have been approved for treatment of glaucoma: timolol, betaxolol, levobunol and carteolol. Because of the possible side effects, they should be avoided in patients with asthma or decompensated heart failure.

Alpha-adrenergic agonists also decrease the production of AH, activating presynaptic adrenergic receptors in the ciliary body and inhibiting the release of noradrenaline. Sympathomimetics have shown not only to block the inflow of AH, but also to increase the uveo-scleral outflow.

Prostaglandin (PG) analogs are first-line, along with beta-blockers, drugs for treatment of ocular hypertension. PG analogs work by increasing the outflow of AH, especially through the uveoscleral pathway Topical treatment with PG analogs is not associated to systemic side effects. PG analogs local side effects are mostly not severe: changes in eye color, increase eyelash length, eye redness, itching, burning, impaired visual function.

Additional IOP-lowering drugs include cholinomimetics, such as pilocarpine, and carbonic anhydrase inhibitors, including acetazolamide. Cholinomimetics act by contracting the ciliary muscle, which opens the TM, increasing the outflow of AH.

Carbonic anhydrase inhibitors decrease production of AH, inhibiting the release of HCO_3^- in the posterior chamber.

Research is focused on development of neuroprotective therapies, which could stop the disease and even restore visual function through the regeneration of cells lost.

AGE-RELATED MACULAR DEGENERATION (AMD)

During the natural process of aging, the human eye undergoes physiological changes that include changes in the distribution of photoreceptors (30% loss of rod photoreceptors [24]), thickening of Bruch's membrane (BM) (10) and accumulation of retinal pigment epithelium (RPE) debris, including drusen (11-15) composed by esterified cholesterol, phospholipids, lipofuscin, inflammatory components and other intra- and extraocular degenerative materials (16, 17, 18).

Age-related macular degeneration (AMD) is a progressive degenerative disease of the central part of the retina (the macula), a small, pigmented area responsible for visual acuity. Damage to the macula results in central vision loss. It is most common among people 55 years of age and older and is the leading cause of blindness among the elderly in developed countries. Risk factors implicated for AMD include older age, smoking, genetic predisposition and cardiovascular disease.

Initial modifications of AMD are seen as focal hyperpigmentation of the RPE and accumulation of sub-RPE deposits, including drusen, both between BM and the RPE and within the RPE itself (Figue 4).

The histopathology and clinical progression contribute to the definition of four major AMD subtypes (19-21):

1. Early AMD;
2. Intermediate AMD;
3. Advanced non-neovascular ("dry" or geographic atrophy) AMD;
4. Advanced neovascular ("wet" or exudative) AMD.

Early AMD is characterized by few small or medium-sized drusen and pigmentary abnormalities in the RPE, resulting in either mild visual impairment or can be asymptomatic. The transition from early to intermediate AMD occurs with the appearance of at least one large druse. At this point, the disease can progress to one of the two advanced forms of AMD: dry AMD (non-neovascular), characterized by presence of drusen and atrophy of the RPE and choroid; or wet AMD (neovascular), with newly formed vessels and RPE detachment.

The result of both of these processes (gradually in the dry form and suddenly in the wet form) is photoreceptor cell death and vision loss.

Diagnostic evaluation

Fluorescein angiography has been the gold standard for detecting and confirming the presence of neovascularization. However, it is an invasive imaging test in which serial retinal photographs are taken after fluorescein dye is injected into a vein. Optical coherence tomography (OCT) is a non-invasive method of imaging for posterior structures of the eye, frequently used to detect and monitor morphological changes associated with choroidal neovascularization.

Treatment opstions

Experimental and clinical evidence has shown that vascular endothelial growth factor (VEGF) is a key component in promoting neovascularization. Drugs that block vascular endothelial growth factor-A (VEGF-A) have shown to be effective in neovascular AMD. These drugs, administered through intravitreal injection, act by decreasing accumulated fluid in the back of the eye and by causing regression of the new fragile vessels.

Available medications in this class include ranibizumab (Lucentis, Genentech Inc.), bevacizumab (Avastin, Genentech Inc.), and aflibercept (Eylea, Regeneron Pharmaceuticals, Inc.) (Table 2) (22).

Ranibuzimab is a recombinant, humanized, monoclonal, antibody fragment that inhibits all VEGF-A isoforms. Bevacizumab is a monoclonal, humanized, VEGF-specific antibody, developed for various cancers and used off-label for treatment of neovascular AMD (Figure 5). Treatment with ranibizumab or bevacizumab usually requires monthly injections into the eye or injections given as needed on the basis of monthly assessments to monitor disease activity.

Frequent eye injections may result in rare but serious adverse events. The effectiveness (23) and safety (24) of ranibizumab and bevacizumab for the treatment of patients with neovascular AMD have been analyzed in published Cochrane reviews and documented to be similar.

Aflibercept (VEGF-Trap), a relatively new medication for neovascular AMD, is a fusion protein made of key domains of VEGF receptors 1 (VEGFR1) and 2 (VEGFR2) fused with a portion of human antibody (25). Unlike ranibizumab and bevacizumab, aflibercept binds VEGF-A, VEGF-B, and another protein - placental growth factor (PIGF) - that is believed to play a role in progression of neovascular AMD. The binding affinity of aflibercept for VEGF is stronger than that of bevacizumab or ranibizumab (26), leading to potentially

longer duration of action in the eye that allows longer intervals between treatments. Less frequent dosing should lead to reduction in the risk of harm associated with intraocular injections.

Figure 4: Diagram of the outer layers of the human central retina in normal and in AMD (Tan et al. Human Genomics. 2016). As the disease progresses, Bruch's membrane (BM) increases in thickness. Early AMD is associated with small drusen and retinal pigmented epithelium (RPE) pigment abnormalities. As the disease progresses to the intermediate form, additional drusen are observed. In the two late forms of AMD (dry and wet), there is extensive drusen and photoreceptor cell death, with atrophy of the RPE and choroid in the dry form and choroidal neovascularization (CNV), hemorrhaging, and RPE detachment in the Wet form.

Figure 5: Ranibizumab and bevacizumab structure, developed from the same antibody.

Drug (company)	Ranibizumab (Genentech; Novartis)	Bevacizumab (Genentech; Roche)	Aflibercept (Regeneron; Bayer)
Molecular weight	48 kDa	149 kDa	115 kDa
Half-life (serum)[23]	4.75 days	8.25 days	18 days
Half-life(vitreous)	2.75 days[24]	4.9 days[25]	7.1 days[23]
Affinity to VEGF165[23]	Kd 46 Pm*	Kd 58 Pm	Kd 0.49 Pm
Inhibit	VEGF-A	VEGF-A	VEGF-A; VEGF-B; PlGF
Vial dose and volume	2.3 mg in 0.23 mL	100 mg in 4 mL	4 mg in 0.1 mL
AMD regimen	0.5 mg monthly	1.25 mg monthly	2 mg monthly 3 times then bimonthly
Injection volume	0.05 mL	0.05 mL	0.05 mL
No. injections in year 1	12	12	8

Table 2: Comparative anti-VEGF medications with the approved protocols for wet AMD (Mansour AM, et al. Br J Ophthalmol 2015). *Affinity expressed as equilibrium dissociation constant (KD) in the picomolar (Pm) range. AMD, age-related macular degeneration; PlGF, placental growth factor.

MiRNAs

Gene expression is largely regulated, in particular by transcription factors (TFs) and their binding sites (TFBSs). Recently, another group of molecules, namely microRNAs (miRNAs), have been found to regulate gene expression at the post-transcriptional and translational levels through interaction with target messenger RNAs (mRNAs) (38).

MiRNAs belong to a class of non-coding small RNAs. The first miRNA was found by Victor Ambros and his colleagues (39, 40). Its mature sequence contains only 21~24 nucleotides. The miRNA precursors are converted to mature miRNA duplexes through sequential processing by the RNaseIII family of endonucleases Drosha and Dicer (41, 42). (Figure 6). They bind to the 3'-untranslated regions (3'-UTRs) of target mRNAs through base pairing to complementary sequences, resulting in the cleavage of target mRNAs or repression of their translation (43-45). Translational inhibition, which seems to be the major mode of action, is performed by a riboprotein complex called RNA-induced silencing complex (RISC) consisting of the miRNA and proteins of the argonaute family (46-48). One miRNA can have multiple target sites in the mRNA transcript, while one mRNA can be targeted by multiple miRNAs.

The human genome has been estimated to encode up to 1000 miRNAs that regulate approximately one third of human genes, and each miRNA could target more than 200 genes (49, 50).

Emerging in vivo and in vitro experiments are showing that miRNAs regulate various cellular processes, including differentiation, development, aging, apoptosis, oncogenesis and metabolism (51-56). Expression studies have shown that miRNAs have expression patterns tissue-specific or developmental-stage-specific (57, 58).

Moreover, the dysregulation of specific miRNAs has been associated with a variety of diseases. miRNAs are shown to play important roles in tumorigenesis, with some miRNAs acting as oncogenes and some as tumor suppressor genes. miRNA profiles differ between normal tissues and tumor tissues and among tumor types (59-62) and can be used to accurately identify tumor tissue origin and prognosis.

Several studies suggest that some miRNAs are differentially expressed in human brain and regulate the expression of genes associated with specific neurodegenerative disorders,

whereas just few studies are available about miRNA deregulation in ocular degenerative diseases.

MiRNAs have been detected in body fluids such as blood, saliva or urine (63). Circulating miRNAs, found in plasma or serum, could be involved in cell-cell signaling [48]. Since they can be easily evaluated through a blood draw, they could represent potential minimally invasive biomarkers used for screening and/or monitoring diseases (64).

Moreover, novel classes of chemically engineered oligonucleotides, termed ''antagomirs'' or ''antimiRs'', have been developed and proved to be efficient in the modulation of miRNAs levels, representing potentially future treatment options.

Therefore, identification of different pattern of miRNAs expression could be a potential approach in order to develop novel biomarkers and to discover pharmacological targets in human diseases, such as age-related neurodegenerative diseases.

Finally, once their role in the pathogenesis of human diseases will be definitely clarified, miRNAs could represent novel targets for drug development.

Figure 6. miRNA biogenesis and functions (S. Xu et al. 2009). In the nucleus, the primary transcript of miRNA, pri-miRNA, is transcribed by RNA polymerase II (A). Many miRNAs are derived from introns of protein-coding genes (B). The pri-miRNAs fold into hairpin structures, which are cleaved by an RNase III endonuclease, Drosha in the Drosha-DGCR8 complex, to form 60–70-nt intermediates, known as pre-miRNAs. Pre-miRNAs are transported to the cytoplasm by Ran-GTP and an Exportin 5, and are cleaved by another RNase III endonuclease, Dicer, to form and 22-bp miRNA duplexes. TRBP recruits Agonaute protein, Ago2, to initiate the assembly of the RNA-induced silencing complex (RISC). When the miRNA and the target sites have precise or nearly precise complementarity, miRNAs specify cleavage of the target mRNAs by Ago2; when the base pairing is imperfect, miRNA with the RISC can destabilize the mRNA by deadenylation and subsequent decapping, and repress translation of the targeted mRNA by blocking translation initiation and/or inhibiting elongation.

MiRNA expression in the eye

The role of miRNA in the development and function of the eye is not well understood but is currently being explored and several reports on miRNA expression in retina and other ocular tissues, e.g. lens and cornea, helped to define it better.

A lot of miRNAs highly expressed in the mouse retina have been identified (65, 66).

In a group of inherited retinal degenerations, characterized by progressive photoreceptor loss and visual impairment and known as retinitis pigmentosa (RP), an altered pan-retinal expression of specific miRNAs has been identified, suggesting a potential involvement of miRNAs in this retinal disease (67).

Moreover, miRNAs have been identified in human blood samples and in many ocular tissues and showed to play a role in lens and retina development, ocular physiology, and several ocular diseases.

Increasing research efforts on small RNAs suggests that dysregulated miRNAs may regulate key aspects of AMD pathology. Data on circulating miRNA in AMD are still limited: four studies published between 2014 and 2016 analyzed the circulating miRNA expression profiles of AMD patients but showed little overlap in the findings.

Findings on dysregulated ocular miRNA showed more promise. Three studies profiled miRNA from retina samples and RPE cells, and one study reported miRNA measurements from vitreous humor (VH) of AMD patients. MiR-146a was found to be upregulated in both forms of AMD, and in different tissue. It is a well characterized miRNA and has been linked to progressive, age-related, inflammatory neurodegenerative disorders (68). It is supposed to modulate innate immune responses, inflammation, and the microglial activation state. It is under transcriptional control by nuclear factor-kappaB (NF-jB), and has been found to be upregulated by reactive oxygen species, pro-inflammatory cytokines, and amyloid peptides. As mir-146a, miR-155 was found to be dysregulated in AMD retina and it is a regulator of inflammation and microglial activation state in response to stress.

Recent studies revealed that a number of miRNAs are involved in the process of angiogenesis (69, 70, 71): miR-31, miR-150 and miR-184 have shown to be downregulated in oxygen-induced retinopathy mice models; angiogenesis and response to varying oxygen levels resulted to be modulated by miR125b, and miR-17, which may also regulate apoptosis.

These key candidate miRNAs could be useful as novel therapeutic approaches in AMD (64).

Finally, miRNA-based novel treatment of retinal and ocular diseases may be developed once the roles of miRNAs in the pathogenesis of these diseases will be identified.

CHAPTER I

microRNA target prediction in glaucoma

Giovanni Luca Romano[1*], Chiara Bianca Maria Platania[1*], Stefano Forte[2], Salvatore Salomone[1], Filippo Drago[1], Claudio Bucolo[1]

[1]Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy;

[2]IOM Ricerca srl, Viagrande-Catania, Italy.

Abstract

Glaucoma is a progressive optic neuropathy and it is one of the leading cause of blindness in the industrialized countries. The aim of the present study is to investigate miRNA regulation in glaucoma and other neurodegenerative diseases, that share similar pathways, by means of in-silico approaches such as bibliographic search and access to bioinformatic resources. First of all, data mining was carried out on Human miRNA Disease Database (HMDD) and mir2Disease databases. Then, predictions of deregulated miRNAs were carried out accessing to microrna.org database. Finally, the potential combinatorial effect of miRNAs, on regulation of biochemical pathways, was studied by an enrichment analysis performed by DIANA-miRPath v.2.0. We found, from literature search, 8 deregulated miRNAs in glaucoma, 9 and 23 in age-related macular degeneration (AMD) and Alzheimer's disease (AD), respectively. One miRNA is commonly deregulated in glaucoma and AMD (miR-23a). Two miRNA (miR-29a, miR-29b) are common to glaucoma and AD, and four miRNAs where identified to be commonly deregulated in AMD and AD (miR-9, miR-31, miR-21, miR-34a, miR-146a). The match of the miRNA common to glaucoma and the other two neurodegenerative diseases (AMD and AD) did not generate any output. Enrichment of information has been reached through miRNAs prediction: 88 predicted miRNA are common to glaucoma and AMD; 19 are common to glaucoma and AD, 9 are common to AMD and AD. Indeed predicted miRNA common to the three neurodegenerative diseases are 9 (miR-107, miR-137, miR-146a, miR-181c, miR-197, miR-21, miR-22, miR-590, miR-9). DIANA-miRPath predicted that those nine miRNAs might regulate pathways involved in inflammation. The findings hereby obtained provide a valuable hint to assess deregulation of specific miRNA, as potential biomarkers and therapeutic targets, in glaucoma and other neurodegenerative diseases by means of preclinical and clinical studies.

Introduction

Glaucoma is a progressive optic neuropathy and it is one of the leading cause of blindness in the industrialized countries. Aging is one of the mainly recognized risk factor of glaucoma, and it has been proposed to have a neurodegenerative imprint. Incidentally, aging is also a risk factor to develop Alzheimer disease (AD), a well-known neurodegenerative pathology, characterized by accumulation of amyloid plaques. An important characteristic common to both diseases is amyloid β (Aβ) deposition in the brain and in the retina of AD and glaucoma patients, respectively. In glaucoma loss of retinal ganglion cells (RGCs) seems to be preceded by axonal atrophy and deficits in axonal transport (Buckingham et al., 2008; Calkins, 2008). This pattern of disease progression, from axonal degeneration and progressing through secondary degeneration, is also observed in AD. Interestingly, Aβ and phosphorilated tau (p-tau), proteins that aggregate respectively in plaques and neurofibrillary tangles in the brain of AD patients, have been detected also in glaucomatous patients and have been thought to have a role in progression of visual loss and retinal ganglion cells (RGCs) death (Goldblum et al., 2007; Guo et al., 2007; Gupta et al., 2008; Janciauskiene and Krakau, 2001; Yin et al., 2008; Yoneda et al., 2005). Recently, an emerging interest for non-coding RNAs and in particular microRNAs (miRNAs) has been observed. Despite a plethora of studies about the role of miRNA in neurodegenerative diseases, few information are available about miRNA deregulation in ocular degenerative diseases and the common pathways shared with other neurodegenerative conditions. The eye is an extension of the brain and retinal changes have been observed in patients with central nervous system (CNS) disorders such as stroke, amyotrophic lateral sclerosis (ALS), Parkinson disease (PD) and Alzheimer disease (AD). It is noteworthy, that a tight correlation between glaucoma and the above mentioned neurodegenerative disorders has been suggested (Calkins, 2008; Fischer and Glass, 2007; Schwartz et al., 1996). The miRNAs are a family of non-coding single-stranded small RNAs (about 22 nucleotides) (Bartel, 2004). They originate from longer transcripts, pre-miRNA, cleaved by the nuclease Dicer, which generates a double stranded miRNA. A single stranded miRNA is then loaded in the proteinaceous complex RISC (RNA induced silencing complex), that silences gene expression through specific degradation of mRNA transcript, which is then recognized by means of sequence complementary miRNA. Focus on miRNA deregulation in neurodegenerative diseases might provide perspective innovative therapies, considering that neurodegenerative diseases are mainly multifactorial and miRNA target commonly

regulates more than one gene (Maciotta et al., 2013). We aimed our research in miRNA target prediction in glaucoma. Specific biological databases were queried for microRNA functionally involved in glaucoma or neurodegenerative diseases, then information enrichment was carried out searching literature on genetic association in glaucoma. Selected miRNAs were then used for the identification of candidate target mRNA using specific bioinformatics tools. The combinatorial effects of predicted common miRNAs, and their involvement in common biological pathways, have been studied using DIANA-miRPath.

Methods

Data mining of microRNA

We tried to retrieve deregulated microRNA involved in ocular diseases from the Human miRNA Disease Database (HMDD) (Lu et al., 2008) and miR2Disease (Jiang et al., 2009) databases. HMDD is a collection of human miRNA/disease associations supported by experimental results and miR2Disease is a manually curate database, aimed at providing a comprehensive resource of miRNA deregulation in different human diseases. Unfortunately, both HMDD and mir2Disease databases did not show any entry related to glaucoma and other ocular neurodegenerative diseases such as AMD. We included AMD in our investigation because represents another example of neurodegenerative disease characterized by Aβ deposition (Medeiros and Curcio, 2001). Therefore, we proceeded with the approach described ahead. Literature search has been carried out on PubMed and Scopus in order to find miRNAs experimentally involved in glaucoma and AMD. In particular, data associated to clinical studies and preclinical studies involving human cells were collected. miRNA associated to each disease have been matched and represented has a Venn diagram where each intersection includes common miRNA for the diseases analyzed. Deregulated microRNA involved in AD have been retrieved from the HMDD (Lu et al., 2008) and mir2Disease (Jiang et al., 2009) databases.

microRNA target prediction

Hence, in order to increase the information available, we analyzed from literature gene association studies in glaucoma and AMD, then the prediction of targeting miRNAs has been carried out by queries on microRNA.org database (http://www.microRNA.org/) (Betel et al., 2008). Predictions are carried out based on a development of the miRanda algorithm; predicted binding sites are then scored with the machine learning method mirSVR (Betel et al., 2010). Those predicted miRNA, putatively involved in glaucoma and AMD, have been matched with miRNA deregulated in AD. Data analysis, on 236 retrieved miRNAs, has been performed with Microsoft Excel 2010.

Identification of putatively involved common pathways.

The potential combinatorial effect of miRNAs, in regulation of biochemical pathways, was studied by an enrichment analysis performed through DIANA-miRPath v.2.0 (Vlachos et al., 2012). This bioinformatic tool calculates the probability for each miRNA to be significantly associated to a KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway. DIANA-miRPath, given a list of microRNA, goes back to target genes by means of two different algorithms: miRTarBase (Hsu et al., 2011) and microT-CDS (Reczko et al., 2012). The algorithm miRTarBase gives as output experimentally verified targets; whereas microT-CDS predicts extra targets based on matching of microRNA in coding sequences (CDS) of mRNA. Therefore, the software performs and enrichment analysis of KEGG pathways regulated by miRNAs. Pathways predicted with microT-CDS are listed along with p-values, number of genes and miRNAs. We, hereby, report a literature based search along with predicted "TarBase" pathways, in order to corroborate prediction results.

Results

The databases HMDD and miR2Disease did not generate any miRNA as entry associated to either glaucoma or AMD. Thus we have analyzed the current literature about annotated miRNA involved in glaucoma and AMD (Tables 1 and 2), data have been matched with miRNA involved in AD and represented as a Venn diagram (Fig. 1). We found 8 deregulated miRNAs in glaucoma, 9 and 23 in AMD and AD, respectively. One miRNA is

commonly deregulated in glaucoma and AMD (miR-23a). Two miRNA (miR-29a, miR-29b) are common to glaucoma and AD, and four miRNAs where identified to be commonly deregulated in AMD and AD (miR-9, miR-31, miR-21, miR-34a, miR-146a). The match of the miRNA common to glaucoma and the other two neurodegenerative diseases (AMD and AD) did not generate any output.

Hence, we proceeded with prediction of miRNA from genes retrieved from gene association studies in glaucoma and AMD. Analysis of gene association studies are reported in Tables 3 and 4 for glaucoma and AMD, respectively. Predicted miRNAs, that target the reported genes, have been matched with annotated miRNA associated to AD. We found an increased number of common miRNA between glaucoma, AMD and AD. In particular, 88 predicted miRNA are common to glaucoma and AMD; 19 are common to glaucoma and AD, 9 are common to AMD and AD. Indeed predicted miRNA common to the three neurodegenerative diseases are 9 (miR-107, miR-137, miR-146a, miR-181c, miR-197, miR-21, miR-22, miR-590, miR-9).

Pathways identified through the algorithm microT-CDS are shown in Table 5. Pathways involved in autoimmunity, BRB and BBB integrity, and trophism of nervous systems are represented. Within such pathways there is the Erb B signaling, that seems to have a role in axonal regeneration (Evangelopoulos et al., 2009; Leinster et al., 2013; Tsai et al., 2010), has shown high number of involved genes, good p-value (7.3 E-8), and 10 regulatory miRNA (miR-107, miR-137, miR-146a-5p, miR-197-3p, miR-181-5p, miR-21-3p, miR-22-3p, miR-22-5p, miR-590-3p, miR-590-5p). Those results corroborate the neurodegenerative etiology of glaucoma common to AMD and AD. Interestingly the microT-CDS algorithm identies for glaucoma, AMD and AD the VEGF signaling pathway (p-value 7.7 E-6, 26 target genes, 10 miRNAs).

Therefore, we predicted the association of these 9 common miRNA to KEGG pathways through TarBase annotation; those results are represented in Fig. 2. The most representative KEGG pathways (higher number of associated miRNA and best p-values) are: "apoptosis", "cytokine-cytokine receptor interaction", "Toll-like receptor signaling pathway", "NF-kappa B", "HIF-1" and "neurotrophins". Incidentally, other pathways are also (well) represented and experimentally identified such, TGF-β, hypoxia inducible factor-1, chemokine signaling, and the pathways related to cell cycle regulation (e.g. p53) (Fig. 2).

The prediction of involved pathways, associated to predicted miRNA common to glaucoma, AMD and AD seems to be supported by literature as it follows.

Apoptosis

Even if apoptosis triggering factors are not well characterized, programmed cell death is widely recognized to have a pathological role in neurodegenerations (Yuan and Yankner, 2000) such as AD, whose the most recognized cause is Aβ-induced neurotoxicity. Although elevated intraocular pressure IOP is the most recognized risk factor of glaucoma, retinal ganglion cells death in glaucoma related to apoptotic events might be due to factors besides the mechanical damage, (Qu et al., 2010) such as Aβ toxicity (Guo et al., 2007) and aging (Buckingham et al., 2008). The hypothesis of neuroprotective therapies (Baltmr et al., 2010) along with development of early diagnosis methods for glaucoma are growing. In fact, Normando et al. have developed an early non-invasive diagnostic method to detect in-vivo apoptotic retinal ganglion cells, this method was useful in several preclinical models of glaucoma and a phase I clinical trial has been scheduled to start soon (Normando et al., 2013). The role of apoptosis in AMD is not straightforward to describe. Recently, pharmacological inhibition, knockdown and gene knockout (KO) of c-Jun N-terminal kinase JNK1 has been reported to reduce apoptosis and choroidal neovascularization (CNV) in AMD animal model (Du et al., 2013). However results are strictly dependent from animal model and type of AMD (dry, wet or geographic macular atrophy), because of apoptosis could be beneficial to control vessels growth in wet AMD (Kaplan et al., 1999). Furthermore, it has been reported, through a bioinformatic analysis of gene expression profiles, that the apoptotic pathway was up-regulated in geographic atrophy and in CNV but not in other AMD types, where cell death might be related to necrosis or autophagy (Makarev et al., 2014).

Cytokine-Cytokine receptor interaction

It is well-known that increases in the production of pro-inflammatory cytokines, primarily including TNF-α, are hallmarks of inflammation in glaucomatous neurodegenerative process, although a cause-effect relationship remains to be validated (Yang et al., 2011). TNF-α through the binding of TNFR1, a death receptor, exhibits important links to glial

activation response, mediation of RGCs death, and inflammatory processes during the neurodegenerative injury in glaucoma (Tezel, 2008). Among inflammatory cytokines, TNF-α has been found to have a role in mediating differential cell response to glaucomatous injury. RGCs underwent to TNF-α mediated apoptosis whereas activated glial cell survived. Kinase activity is crucial for the establishment of a balance between cell death signaling and cell survival. In particular, increased phospho-JNK and phospho-p38 have been found to shift the balance toward RGCs apoptotic cell-death; whereas sustained ERK signaling in glial cells has accounted to cell survival. HSPs expression (heat shock proteins) along to ERK, MAPKs and NF-kb signaling and have shifted the TNF-α balance toward cells survival (Tezel, 2008).

Although the brain is an immune privileged site, pro-inflammatory cytokines and their interaction with corresponding receptors have been found to mediate inflammation in ocular neurodegenerative disease as well as in AD (Gebicke-Haerter et al., 2001; Janelsins et al., 2008; Pocock and Liddle, 2001; Vukic et al., 2009). However, whether the inflammation is a consequence of AD or has a role in initiation and triggering of the disease it has not been univocally stated.

It has been found a link between apoptosis and cytokines; certain caspases, effectors of apoptotic pathways, have been associated to immune-mediated inflammation and caspase activation is associated to maturation of inflammatory cytokines (Keller et al., 2008). Caspase 8 and caspase 3/7 have been found to be up-regulated in frontal cortex of AD patients; and the inhibition of this caspases has been found to be beneficial, hindering microglia activation (Burguillos et al., 2011). Cytokines are also known to promote matrix metalloproteinases expression, in particular MMP-9, which have a role in parenchymal infiltration promoting BBB (Vandooren et al., 2014) and BRB breakdown (Abu El-Asrar et al., 1998; Brown et al., 1994; Grant et al., 1998; Grieshaber and Flammer, 2007; Plantner et al., 1998; Steen et al., 1998). Inflammation has been hypothesized to affect the incidence and progression of AMD, along with oxidative stress and endothelial dysfunction, thus several inflammation markers have been recently evaluated in an epidemiological study (Klein et al., 2014). In this study inflammatory markers and one marker of endothelial dysfunction were found to be modestly associated with the 20-year cumulative incidence of early AMD. Those data may provide a hint to the inflammatory etiology of AMD, however whether inflammation is a cause of a consequence of AMD has not been yet established. Interestingly Aβ, found in drusen of AMD patients, has shown pro-inflammatory action in

in-vivo models of AMD (Liu et al., 2013). Furthermore TNF-α and other inflammatory cytokines have been found to influence VEGF expression and vascularization in human retinal pigmented epithelial cells (Nagineni et al., 2012).

Toll-like receptor signaling pathway

Toll-like receptors (TLRs) trigger innate inflammatory response through activation of NFkB-mediated expression of cytokines, i.e TNF-α, IL-1β, IL-8 and CCL5 (van Noort and Bsibsi, 2009). TLRs exogenous ligands are mainly conserved molecules derived from bacteria; whereas endogenous ligands are molecules released from damaged cells and are called damage-associated molecular patterns (DAMPs) (i.e. HMGB1 and HSPs) (Takeuchi and Akira, 2010). TLRs appeared to be expressed in neuronal cells in condition were no foreign invaders are obvious, such as CNS of Alzheimer patients (Walter et al., 2007) and in case of multiple sclerosis (Bsibsi et al., 2002). As reported previously activation of caspases 8 and 3/7, that are activated in AD and Parkinson patients brains, has been mediated by inflammation and this signaling has been initiated by activation of TLR4 receptor. TLR4 is activated mainly by non-microbial ligands, i.e. DAMPs. TLR4 has shown a role in JNK induced neuronal apoptosis mediated by Aβ and the lipid peroxidation product 4-hydroxynonenal (HNE). In fact, Aβ and HNE were found to induce TLR4 expression in cortical neuronal cells sensitizing neurons to apoptotic cell death (Tang et al., 2008). The role of TLR4 in a animal model of acute glaucoma has been recently elucidated (Chi et al., 2014). In particular, elevated IOP increased expression of TLR4 and initiated the expression of caspase-8 and NLRP1/NLRP3 inflammasome along with production of IL-β, thus characterizing the involvement of innate immunity in a non-microbial stimuli such as IOP-induced ischemia. In the described study TLR4 inhibition attenuated RGC apoptotic death.

Several gene-association studies did not confirm an association of TLRs to AMD (Despriet et al., 2008; Edwards et al., 2008; Klein et al., 2010). However in 2011 Kleinman has found that siRNA (21 nt long) led to RPE degeneration through activation of TLR3 and related caspase 3 activation, developing a animal model of geographic atrophy. Shorter, 16 nt, siRNA did not elicited such cytotoxicity (Kleinman et al., 2012). Those results led to a further small epidemiological study, where Chinese patients with wet AMD showed increased TLR2/3 expression and reactivity in peripheral blood monuclear cells (PBMCs)

in comparison to control patients. At least this last study might provide hints for the validation of toll-like receptors as biomarker. The role of TLRs in macular degenerations has been further investigated for geographic atrophy by the group of Jayakrishna Ambati from University of Kentucky. In particular, the microRNA processing enzyme DICER1 was reduced in the RPE of GA eyes leading to abundance of *Alu* RNA transcripts which led to RPE death with mechanism that is, however, independent from TLRs (Kim et al., 2014). However, inhibition of TLR4 receptor has been found to be beneficial in a transgenic model of retinal degeneration (Abca4$^{-/-}$ and Rdh8$^{-/-}$ mice) (Kohno et al., 2013).

NF-kB pathway

Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is a protein complex, which controls DNA transcription. Genotoxic, inflammatory and oxidative stresses activate NF-kB and aberrant NF-kB signaling has been documented in numerous age-related diseases including neurodegeneration and diabetes (Tilstra et al., 2011). The most potent activators of NF-kB are TLRs, as well as TNF-α and IL-1. NF-kB promotes inflammation through transcription of inflammatory mediators. Inflammatory response, mediated by Aβ, has been shown to be dependent from NF-kB activation (Combs et al., 2001), and activation of microglia by Aβ has been shown to sustain NF-kB activation leading to neuronal cell death (Chen et al., 2005). However, whether NF-kB inhibition would be detrimental or beneficial to cell survival is not well established; because NF-kB belongs to the TNF-α signaling, where many effectors proteins play a role in cell death/survival balance. As reported by Yang X. in 2011 (Yang et al., 2011), an extended proteomic analysis on specimens of glaucomatous eyes showed that NF-kB pathway was activated. NF-kB plays an essential role as key regulator of neuronal survival programs in TNF-α (Beg and Baltimore, 1996), however it should be stated that NF-kB functions are strictly dependent on cell-specific factors and unbalanced activation of different subunit complexes (Hayden and Ghosh, 2008). Besides that, the beneficial activation of NF-kB on RGC survival along with neuroprotection mediated by pigmented-epithelium-derived-factor PEDF has been recently reported by Unterlauft et al 2014 (Unterlauft et al., 2014). NF-kB translocation to nucleus, has been reported in several AMD models such as retinal iron-induced oxidative stress (Rodriguez Diez et al., 2013) and laser-induced CNV (Lu et al., 2014). In the iron induced oxidative model of retinal degeneration, NF-kB translocation

was modulated by cytosolic PLA2 (cPLA2) and by secretory PLA2 (sPLA2). In that model it has been found that sPLA2 acts as both a pro-inflammatory and anti-inflammatory enzyme, respectively inducing NF-kB and decreasing the activity of COX-2. NF-kB activation was found in the laser-induced CNV; inhibition of IKK2 and relative inhibition of traslocation of NF-kB led to reduced CNV. Although, inhibition of NF-kB was generally associated to cell apoptosis induced by TNF-α, the ARPE-19 cells of the mentioned study did not undergo to apoptosis.

A recent study shows that human ARPE-19 cells underwent to cytotoxicity upon treatment with lysosome destabilizers, which are able to activate NLRP3 inflammasome via the NF-kB pathway (Tseng et al., 2013). NLRP3 inflammasome has been found to be expressed in retina of AMD and GA patients but not in control eyes. Thus inflammasome activation along with NF-kB seems to have a pathological role in macular degenerations. The presented data about the involvement of NF-kB in macular degeneration suggests that NF-kB has a mainly a detrimental pro-inflammatory action; however more information are needed e.g from different animal models of AMD along with focused experimental protocols.

HIF-1 pathway

The hypoxia-inducible transcription factor (HIF) complex is a heterodimer composed of a constitutive HIF-1β subunit and a inducible subunit HIF-1α, both subunits belong to the family of aryl hydrocarbon receptor nuclear translocators (ARNT). Under normoxia, HIF-1α undergoes to proteasomal degradation, because of it is hydroxylated at specific proline residues leading to immediate ubiquitination. HIF-1α hydroxylation is mediated by prolyl hydroxylases PHDs, which require Fe(II) as cofactor. On the contrary, under hypoxia, HIF-1α hydroxylation is suppressed and HIF-1α can accumulate and traslocate into the nucleus where it binds to HIF-1β regulating transcription of several genes (Weidemann and Johnson, 2008). HIF-1 regulates genes involved in anaerobic metabolism (glucose transporters GLUT1/3, glycolysis enzymes), in angiogenesis (VEGF) and pH regulation (carbonic anhydrase) (Yee Koh et al., 2008). HIF-1 has been found to regulate pro-apoptotic genes, however this regulation depends mainly on the type of injured tissues (Wang et al., 2009). .Despite its name, HIF-1 is induced not only in response to reduced

oxygen availability but also by other stimulants, such as nitric oxide, or various growth factors(Kanehisa et al., 2014). The molecular mechanism that link hypoxia to neurodegeneration, e.g in AD, is not well clear. Hypoxic/ischemic events up-regulate the amyloid precursor protein (APP); leading to an increase of APPα, that is neuroprotective, but also to accumulation of Aβ which is neurotoxic. In addition, the stabilization of the complex HIF-1 by means of inhibition of PHDs activity, through iron chelation, has been shown to reduce progression of disease in AD patients (Ogunshola and Antoniou, 2009). Furthermore, the HIF induction and signaling pathways were found to be down-regulated with aging (Chavez and LaManna, 2003). In glaucoma vascular abnormalities and altered blood flow at the optic nerve head (vascular hypothesis of glaucoma) have been claimed to lead to RGCs death due to local hypoxia similarly to AD (Flammer et al., 2002). Thus, the HIF1 is thought to be involved in the pathology of glaucoma; increased presence of HIF-1α was found in glaucomatous eyes and this protein was found to be co-localized in regions of visual field defects (Tezel and Wax, 2004). In addition, it was recently observed in a animal model of glaucoma (optic nerve axotomy), that inhibition of oxidative stress led to decreasing expression of HIF-1α and increased RGCs survival. Although, retinal ischemia does not seem to have a role in subretinal neovascularizations such as CNV, HIF-1 has been found to be stabilized and promote expression of VEGF in AMD models. HIF-1 stabilization in AMD likely occurs under oxidative stress condition that affect RPE and photoreceptors. In fact, ROS (reactive oxygen species) were found to inhibit PHDs (Campochiaro, 2013).

NT pathway

Neurotrophins (NT) are a family of proteins that regulate the growth, survival and morphology of the populations of neurons in the adult brain. Damage related to many neurodegenerative diseases are developed through a malfunction of neurotrophins pathway. Four different families of neurotrophins have been characterized so far: Nerve growth factor (NG); Brain-derived neurotrophic factor (BDNF); neurotrophin 3; neurotrophin 4. Two types NT receptors have been identified: tyrosine kinase (Trk) and p 75 neurotrophin (p75[NTR]). Activation of Trk receptor leads to a series of intracellular signaling cascades that include MAPK, PI-3 kinase, and PLC, mediating signals of positive type as the enhanced survival and growth. On the contrary, p75[NTR] would mediate cell survival and cell death signaling. The involvement of BDNF and NGF in the pathogenesis of AD was underlined

by a number of studies. However, early studies did not show an decreased level of NGF in AD brains. The involvement of NGF in AD is likely to be related to the impaired retrograde transport of NGF. Furthermore, the correlation between BDNF deficiency and AD is to be confirmed, because of BDNF mRNA and protein levels are essentially poorly expressed in the cortex and hippocampus of patient with AD (Allen et al., 2013). The neuroprotective role of NGF in experimental models of glaucoma was extensively investigated (Roberti et al., 2014). Lambiase et al. in 1997 (Lambiase et al., 1997) showed that retro-ocular administration of NGF led to reduced RGCs loss in an animal model of glaucoma. In another study, it was shown that NGF eye drops (200 ug/ml) were effective in promoting RGCs survival in a rat model of glaucoma (Sposato et al., 2009). However, the transport mechanism of NGF from ocular surface to posterior chamber of the eye it is not clear. The protective role of NT and NT receptor in glaucoma was supported by a recent study: brimonidine an IOP lowering drug (α2 adrenergic receptor agonist) was found to lead to neuroprotection by increasing the expression of Trk in a animal model (optic nerve injury) (Fujita et al., 2013). In AMD, neurodegeneration occurs at photoreceptors after sustained insult to RPE due to chronic inflammation and muller cells active gliosis has been implicated in secretion of pro-inflammatorry mediators. It was found in a inducible transgenic animal model of AMD (muller cell ablation), but not in control animals, that pro-neurotrophin/P75^{NTR} pathway is activated leading to increased inflammation (Shen et al., 2014). A recent work reports miRNA profiling in the same animal model of AMD described above (Chung et al., 2015). The miRNAs that are deregulated in this animal model were indentified to regulate NT pathways along with others such as p53, Jak-stat and chemokine signaling pathways.

Discussion

There is an emerging interest in find a sort of *fil rouge* between ocular and CNS neurodegenerative diseases. Anatomically and developmentally the eye is considered a projection of CNS. The retina is characterized by layers of differentiated neurons where RGCs collect information from the outermost layer. Although RGCs have distinct morphology, they bear similar characteristics of CNS neurons such as cell body dendrites and axon. RGCs axons form the optic nerve, that is not a peripheral nerve since it is covered with myelin and as well as CNS fibers is enclosed by the three meningeal layers

(Berson, 2008). Furthermore, along to similarities between the blood brain barrier (BBB) and the blood retinal barrier (BRB), the eye, as an immune-privileged site and it shares with CNS other closely related characteristics (London et al., 2013). Several CNS neurodegenerative diseases, such as AD (Sivak, 2013), present ocular manifestations. Moreover, efforts are currently undertaken in order to use non-invasive approaches to be used by ophthalmologists for AD diagnosis [ClinicalTrials.gov, ID NCT01555827]. In this view, the characterization of some ocular disorders as neurodegenerative disease is not only challenging but also promising in searching of elucidation of common pathological mechanisms, novel diagnostic and therapeutic approaches.

The idea that neurodegenerative disease can be considered an RNA disorder, (Johnson et al., 2012) related to miRNA deregulation, is growing. Furthermore, deregulation of miRNA might be connected to aging and susceptibility to cellular stress (Emde and Hornstein, 2014). Several laboratories have shown significant changes in expression of some miRNAs in the brain of AD patients. Down-regulation of these miRNAs is believed to contribute to increased production and accumulation of amyloid-β in these brains.

A therapeutic approach aimed at dysregulated miRNA is promising; however, so far only one miRNA-directed therapy (antagomir) has completed a phase II clinical trial (ClinicalTrials.gov NCT01200420) for treatment of HCV. Furthermore efforts are ongoing for identification of miRNA associated to several diseases, and several trials are registered in order to identify miRNA in different diseases (ClinicalTrials.gov). Identification and validation of deregulated miRNA in neurodegenerative diseases might help in early diagnosis and monitoring of progression. In this view, development of miRNA as biomarker is promising but also challenging because of not all miRNA are circulating in plasma or at least cerebrospinal fluid (CSF) allowing analysis of cell-free samples.

Given the relationship between glaucoma and AD, we hypothesize that in glaucoma, the retina and optic nerve experience changes in miRNA expression similar to those reported in the brain of AD patients. The observation of changes in expression of specific miRNAs associated with glaucoma should be useful in elucidating the pathogenic mechanisms involved in the loss of RGCs and could identify novel therapeutic targets.

Furthermore, it is noteworthy that Aβ has been found also in drusen, that are extracellular deposits in retina of AMD patients. AMD represents one of the leading cause of blindness among the elderly people. In addition, Aβ has been shown to have a role in AMD in

mediation of oxidative stress, inflammation and angiogenesis. In addition, other aggregated proteins have been found either in drusen or Aβ plaques of AD patients, thus AMD could be considered a conformational disease where misfolded proteins mediate neurodegenerative process. (Dentchev et al., 2003; Isas et al., 2010; Johnson et al., 2002). Hence, we included in our bioinformatic study gene association miRNA, either experimentally identified or hereby predicted, involved in AMD. Our bioinformatic approach was also aimed at study the link between neurodegenerative ocular diseases, such as glaucoma and AMD, and CNS neurodegenerative disease such as AD

Signs of irreversible neurodegeneration in glaucoma, AMD and AD, are usually evident at least a decade after onset of disease; thus early diagnosis to start effective therapy against neurodegenerative process is an urgent need. Identification of deregulated miRNA and associated pathways common to glaucoma, AMD and AD might help in the challenging search of biomarkers and therapeutic strategies. In consideration that no or few information report miRNA associated to glaucoma and AMD, whereas there are several studies about deregulated miRNA in AD, we looked at miRNA common to the three diseases by means of bioinformatic methods for prediction miRNAs. Starting from literature search, no miRNA were found to be deregulated in glaucoma, AMD and AD. Prediction of involved miRNAs, allowed the identification of nine, within 236, miRNAs deregulated in glaucoma, as well as in AD and AMD. In order to find a support to link these neurodegenerative diseases, we looked to pathways associated to those nine identified miRNA. We have found interesting results by accessing to DIANA-miRPath. Prediction of pathways with microT-CDS would support the common neurodegenerative etiology of glaucoma, AMD and AD; besides it is intriguing to determine which is the *primum movens* that leads to neurodegenerative process. The VEGF pathway, interestingly, was found to be represented by miRNA common to glaucoma, AD and AMD; thus supporting the vascular hypothesis of glaucoma and AD.

The results about predicted pathways with miRTarBase annotation would help in the identification of the possible *primum movens*. Those pathways, corroborated by the current independent literature, are: apoptosis, cytokine-cytokine receptor interaction, toll-like receptor, NF-kB, HIF-1 and neurotrophin pathway.

Furthermore, most of those pathways are linked to each other and are mainly indicative of an inflammatory response. As regards the predicted pathways associated to putative miRNA common to glaucoma, AMD and AD, we have not information about the direction toward each pathway is deregulated (up-regulated or down-regulated). However this data should be considered as hints of mechanistic information to further investigations.

Inflammation could be the governing principle in glaucoma, AMD and AD. However, as extensively reported in the present study, whether the inflammation is the cause or the consequence or the triggering factor of neurodegenerative process has not been already clarified.

Identification of inflammation as a therapeutic target of neurodegenerative process is critical, because inflammation is a physiological process that can become pathological. It has been stated that sustained tissue para-inflammation (graded state between basal and inflammatory tissue conditions), would lead to chronic inflammatory disease in case of conditions not present in early evolution of humans: high-caloric food intake, low levels of physical activity, exposure to xenobiotic toxic agents and old age (Medzhitov, 2008). Thus neurodegenerative process, with putative inflammatory priming, might be consequence of aging and environmental factors.

Hereby, we report our efforts in search of miRNA associated to glaucoma, as potential biomarkers or therapeutic targets. We hypothesized, based on prediction of miRNA and associated biochemical pathways, that inflammation is one possible therapeutic target common to the three neurodegenerative diseases (glaucoma, AMD and AD). In conclusion, the findings hereby obtained provide a valuable hint to assess deregulation of specific miRNA, as potential biomarkers and therapeutic targets, in glaucoma and other neurodegenerative diseases by means of preclinical and clinical studies.

Table 1. Validated microRNA in glaucoma

microRNA in glaucoma	References
mir-200c	Luna C. et al. PLoS One. 2012 (Luna et al., 2012)
mir-23a	Paylakhi SH. et al. Mol Vis. 2012 (Paylakhi et al., 2012)
mir-29a	Fuchshofer R. et al. Cell Tissue Res. 2012 (Fuchshofer and Tamm, 2012)
mir-24	Luna C. et al. J Cell Physiol. 2011 (Luna et al., 2011)
miR-361 5p	Grassmann F. et al. PLoS One. 2014 (Grassmann et al., 2014)
miR 204	Paylakhi SH. et al. Exp Eye Res. 2013 (Paylakhi et al., 2013)
miR 29b	Tanaka Y. et al. Sci Rep. 2014 (Tanaka et al., 2014)
miR 340	Surgucheva I. et al. J Ocul Biol Dis Infor. 2010 (Surgucheva et al., 2010)

Table 2. Validated microRNA involved in AMD

miRNA in AMD	References
miR 30b	Haque R et al. PLoS One. 2012. (Haque et al., 2012)
miR 23 a	Lin H. et al. Invest Ophthalmol Vis Sci. 2011(Lin et al., 2011)
miR 9	Yoon C. et al. Graefes Arch Clin Exp Ophthalmol. 2014 (Yoon et al., 2014)
miR 146 a	Lukiw WJ. et al. Int J Biochem Mol Biol. 2012 (Lukiw et al., 2012)
miR146 b	Kutty RK. et al. Mol Vis. 2013 (Kutty et al., 2013)
miR 31	Shen J. et al. Mol Ther. 2008 (Shen et al., 2008)
miR 21	Sabatel C. et al. PLoS One. 2011 (Sabatel et al., 2011)
miR 184	Shen J. et al. Mol Ther. 2008 (Shen et al., 2008)
miR 34 a	Hou Q. et al. Invest Ophthalmol Vis Sci. 2013 (Hou et al., 2013)

Table 3. Gene association studies for glaucoma.

Genes	References
Fam125b	Nag A et al. Hum Mol Genet. 2014 (Nag et al., 2014)
F2α	Sakurai M et al. Br J Ophthalmol. 2014 (Sakurai et al., 2014)
MYOC; TMCO1; CYP1B1; FOXC1; PITX2; GAS7	Ojha P et al. Semin Ophthalmol. 2013 (Ojha et al., 2013)
CDKN2B	Burdon KP et al. Ophthalmology. 2012 (Burdon et al., 2012)
OPTN	Liu YH et al. Med Hypotheses. 2011 (Liu and Tian, 2011)
WDR36	Janssen SF et al. Prog Retin Eye Res. 2013 (Janssen et al., 2013)
CAV1; CAV2	Loomis SJ et al. Ophthalmology. 2014 (Loomis, 2014)
SRBD1	Kanemaki N et al. PLoS One. 2013 (Kanemaki et al., 2013)
SIX1	Janssen SF et al. Fluids Barriers CNS. 2014 (Janssen et al., 2014)
SIX6	Ozel AB et al. Hum Genet. 2014(Ozel et al., 2014)

Table 4. Gene association studies for AMD

Genes	References
HGS	Logue MW et al. Neurobiol Aging. 2014 (Logue et al., 2014)
TNF	Logue MW et al. Neurobiol Aging. 2014 (Logue et al., 2014)
RAD51B	Chu XK et al. Age (Dordr). 2014 (Chu et al., 2014)
CFH	Restrepo NA et al. Invest Ophthalmol Vis Sci. 2014 (Restrepo et al., 2014)
CFB	Hutchinson JN et al. Hum Hered. 2014 (Hutchinson et al., 2014)
C3	Duvvari MR et al. PLoS One. 2014 (Duvvari et al., 2014)
ARMS2	Hu Z et al. Br J Ophthalmol. 2014 (Hu et al., 2014)
COL8A1	Seddon JM et al. PLoS One. 2014 (Seddon et al., 2014)
CX3CR1	Gupta D et al. Arch Med Res. 2014 (Gupta et al., 2014)
FBLN5	Stone EM et al. N Engl J Med. 2004 (Stone et al., 2004)

Table 5. DIANA-mirPath. Target predicted with microT-CDS, no TarBase annotation.

KEGG Pathway (microT-CDS)	#genes	#miRNA	p-value
Insulin signaling	56	10	4.8E-13
MAPK	32	11	3.3E-12
TGF-β	35	10	6.7E-12
Prion disease	14	6	9.1E-10
Gap junction	36	10	2.2E-9
GnRH	37	10	2.5E-9
B cell receptor	32	10	7.1E-9
Focal adhesion	71	11	1.4E-8
Ubiquitin mediated proteolysis	52	11	1.9E-8
mTOR	27	8	5.1E-8
ErbB	36	10	7.3E-8
RNA transport	55	10	1.7E-7
Adherence junction	33	11	6.9E-7
VEGF signaling	26	10	7.7E-6
Fc γ R mediated phagocytosis	34	11	1.9E-5
Fc ε RI signaling	27	11	5.4E-5
T cell receptor	38	10	1.1E-4
Adipocytokine	25	7	1.2E-4
Calcium signaling	58	10	2.9E-4
Glutamatergic synapse	45	10	3.4E-4
Regulation of actin cytoskeleton	70	11	5.1E-4
Dopaminergic synapse	45	10	9.0E-4
mRNA surveillance	30	10	1.1E-2
Cell cycle	43	10	1.1E-2
Panthotenate and coA biosynthesis	8	2	1.2E-2
Tight junction	45	9	1.8E-2
Terpenoid backbone synthesis	8	8	1.9 E-2
Retrograde endocannabinoid signaling	39	10	2.0E-2
Wnt	48	11	2.0E-2
Axon guidance	43	11	2.0E-2
Circadian rhythm	13	8	2.2E-2

Fig. 1.

Fig. 2

Figure legends.

Fig. 1. Venn Diagram. Match of annotated microRNA involved in glaucoma, AMD and AD. Red arrows indicate a down-regulation related to the pathology or measured end-points, whereas green arrows indicate up-regulation of those microRNA.

Fig. 2. miRTarBase predicted pathways. Pathways associated to microRNA common to glaucoma, AMD and AD. Solid spheres correspond to predicted pathways. Blue points are the projections of # of genes; red points are the projections # of microRNA, green points are the projections of p-value associated to each pathway. TLR (toll-like receptor); NT (neurotrophin), HIF (hypoxia inducible factor-1), CK/CK-R (cytokine/cytokine-receptor interaction), CC (chemokine).

References

Abu El-Asrar, A.M., Dralands, L., Veckeneer, M., Geboes, K., Missotten, L., Van Aelst, I., Opdenakker, G., 1998. Gelatinase B in proliferative vitreoretinal disorders. American journal of ophthalmology. 125**,** 844-51.

Allen, S.J., Watson, J.J., Shoemark, D.K., Barua, N.U., Patel, N.K., 2013. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacology & therapeutics. 138**,** 155-75.

Baltmr, A., Duggan, J., Nizari, S., Salt, T.E., Cordeiro, M.F., 2010. Neuroprotection in glaucoma - Is there a future role? Experimental eye research. 91**,** 554-66.

Bartel, D.P., 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116**,** 281-97.

Beg, A.A., Baltimore, D., 1996. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274**,** 782-4.

Berson, D.M., 2008. The Senses: A Comprehensive Reference. Vol. 1.

Betel, D., Wilson, M., Gabow, A., Marks, D.S., Sander, C., 2008. The microRNA.org resource: targets and expression. Nucleic acids research. 36**,** D149-53.

Betel, D., Koppal, A., Agius, P., Sander, C., Leslie, C., 2010. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome biology. 11**,** R90.

Brown, D., Hamdi, H., Bahri, S., Kenney, M.C., 1994. Characterization of an endogenous metalloproteinase in human vitreous. Current eye research. 13**,** 639-47.

Bsibsi, M., Ravid, R., Gveric, D., van Noort, J.M., 2002. Broad expression of Toll-like receptors in the human central nervous system. Journal of Neuropathology and Experimental Neurology. 61**,** 1013-1021.

Buckingham, B.P., Inman, D.M., Lambert, W., Oglesby, E., Calkins, D.J., Steele, M.R., Vetter, M.L., Marsh-Armstrong, N., Horner, P.J., 2008. Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma. The Journal of neuroscience : the official journal of the Society for Neuroscience. 28**,** 2735-44.

Burdon, K.P., Crawford, A., Casson, R.J., Hewitt, A.W., Landers, J., Danoy, P., Mackey, D.A., Mitchell, P., Healey, P.R., Craig, J.E., 2012. Glaucoma risk alleles at

CDKN2B-AS1 are associated with lower intraocular pressure, normal-tension glaucoma, and advanced glaucoma. Ophthalmology. 119**,** 1539-45.

Burguillos, M.A., Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J.L., Joseph, B., 2011. Caspase signalling controls microglia activation and neurotoxicity. Nature. 472**,** 319-U214.

Calkins, D.J., 2008. A Neurological Perspective on Glaucoma. How neurodegenerative diseases and glaucoma could be similar. Glaucoma Today. September/October 2008**,** 18-19.

Campochiaro, P.A., 2013. Ocular neovascularization. Journal of molecular medicine. 91**,** 311-21.

Chavez, J.C., LaManna, J.C., 2003. Hypoxia-inducible factor-1alpha accumulation in the rat brain in response to hypoxia and ischemia is attenuated during aging. Advances in experimental medicine and biology. 510**,** 337-41.

Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.F., Kwon, H., Yi, S., Mucke, L., Gan, L., 2005. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. The Journal of biological chemistry. 280**,** 40364-74.

Chi, W., Li, F., Chen, H., Wang, Y., Zhu, Y., Yang, X., Zhu, J., Wu, F., Ouyang, H., Ge, J., Weinreb, R.N., Zhang, K., Zhuo, Y., 2014. Caspase-8 promotes NLRP1/NLRP3 inflammasome activation and IL-1beta production in acute glaucoma. Proceedings of the National Academy of Sciences of the United States of America. 111**,** 11181-6.

Chu, X.K., Meyerle, C.B., Liang, X., Chew, E.Y., Chan, C.C., Tuo, J., 2014. In-depth analyses unveil the association and possible functional involvement of novel RAD51B polymorphisms in age-related macular degeneration. Age. 36**,** 9627.

Chung, S.H., Gillies, M., Sugiyama, Y., Zhu, L., Lee, S.R., Shen, W., 2015. Profiling of MicroRNAs Involved in Retinal Degeneration Caused by Selective Muller Cell Ablation. PloS one. 10**,** e0118949.

Combs, C.K., Karlo, J.C., Kao, S.C., Landreth, G.E., 2001. beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. The Journal of neuroscience : the official journal of the Society for Neuroscience. 21**,** 1179-88.

Dentchev, T., Milam, A.H., Lee, V.M., Trojanowski, J.Q., Dunaief, J.L., 2003. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Molecular vision. 9**,** 184-90.

Despriet, D.D., Bergen, A.A., Merriam, J.E., Zernant, J., Barile, G.R., Smith, R.T., Barbazetto, I.A., van Soest, S., Bakker, A., de Jong, P.T., Allikmets, R., Klaver, C.C., 2008. Comprehensive analysis of the candidate genes CCL2, CCR2, and TLR4 in age-related macular degeneration. Investigative ophthalmology & visual science. 49, 364-71.

Du, H., Sun, X., Guma, M., Luo, J., Ouyang, H., Zhang, X., Zeng, J., Quach, J., Nguyen, D.H., Shaw, P.X., Karin, M., Zhang, K., 2013. JNK inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 110, 2377-82.

Duvvari, M.R., Paun, C.C., Buitendijk, G.H., Saksens, N.T., Volokhina, E.B., Ristau, T., Schoenmaker-Koller, F.E., van de Ven, J.P., Groenewoud, J.M., van den Heuvel, L.P., Hofman, A., Fauser, S., Uitterlinden, A.G., Klaver, C.C., Hoyng, C.B., de Jong, E.K., den Hollander, A.I., 2014. Analysis of rare variants in the C3 gene in patients with age-related macular degeneration. PloS one. 9, e94165.

Edwards, A.O., Chen, D., Fridley, B.L., James, K.M., Wu, Y., Abecasis, G., Swaroop, A., Othman, M., Branham, K., Iyengar, S.K., Sivakumaran, T.A., Klein, R., Klein, B.E., Tosakulwong, N., 2008. Toll-like receptor polymorphisms and age-related macular degeneration. Investigative ophthalmology & visual science. 49, 1652-9.

Emde, A., Hornstein, E., 2014. miRNAs at the interface of cellular stress and disease. Embo Journal. 33, 1428-1437.

Evangelopoulos, M.E., Weis, J., Kruttgen, A., 2009. Mevastatin-Induced Neurite Outgrowth of Neuroblastoma Cells via Activation of EGFR. Journal of Neuroscience Research. 87, 2138-2144.

Fischer, L.R., Glass, J.D., 2007. Axonal degeneration in motor neuron disease. Neuro-degenerative diseases. 4, 431-42.

Flammer, J., Orgul, S., Costa, V.P., Orzalesi, N., Krieglstein, G.K., Serra, L.M., Renard, J.P., Stefansson, E., 2002. The impact of ocular blood flow in glaucoma. Progress in Retinal and Eye Research. 21, 359-93.

Fuchshofer, R., Tamm, E.R., 2012. The role of TGF-beta in the pathogenesis of primary open-angle glaucoma. Cell and tissue research. 347, 279-90.

Fujita, Y., Sato, A., Yamashita, T., 2013. Brimonidine promotes axon growth after optic nerve injury through Erk phosphorylation. Cell death & disease. 4, e763.

Gebicke-Haerter, P.J., Spleiss, O., Ren, L.Q., Li, H., Dichmann, S., Norgauer, J., Boddeke, H.W., 2001. Microglial chemokines and chemokine receptors. Progress in brain research. 132, 525-32.

Goldblum, D., Kipfer-Kauer, A., Sarra, G.M., Wolf, S., Frueh, B.E., 2007. Distribution of amyloid precursor protein and amyloid-beta immunoreactivity in DBA/2J glaucomatous mouse retinas. Investigative ophthalmology & visual science. 48, 5085-90.

Grant, M.B., Caballero, S., Tarnuzzer, R.W., Bass, K.E., Ljubimov, A.V., Spoerri, P.E., Galardy, R.E., 1998. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes. 47, 1311-7.

Grassmann, F., Schoenberger, P.G., Brandl, C., Schick, T., Hasler, D., Meister, G., Fleckenstein, M., Lindner, M., Helbig, H., Fauser, S., Weber, B.H., 2014. A circulating microrna profile is associated with late-stage neovascular age-related macular degeneration. PloS one. 9, e107461.

Grieshaber, M.C., Flammer, J., 2007. Does the blood-brain barrier play a role in glaucoma? Survey of Ophthalmology. 52, S115-S121.

Guo, L., Salt, T.E., Luong, V., Wood, N., Cheung, W., Maass, A., Ferrari, G., Russo-Marie, F., Sillito, A.M., Cheetham, M.E., Moss, S.E., Fitzke, F.W., Cordeiro, M.F., 2007. Targeting amyloid-beta in glaucoma treatment. Proceedings of the National Academy of Sciences of the United States of America. 104, 13444-9.

Gupta, D., Gupta, V., Singh, V., Chawla, S., Parveen, F., Agrawal, S., Phadke, S.R., 2014. Study of Polymorphisms in CX3CR1, PLEKHA1 and VEGF Genes as Risk Factors for Age-related Macular Degeneration in Indian Patients. Archives of Medical Research. 45, 489-494.

Gupta, N., Fong, J., Ang, L.C., Yucel, Y.H., 2008. Retinal tau pathology in human glaucomas. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 43, 53-60.

Haque, R., Chun, E., Howell, J.C., Sengupta, T., Chen, D., Kim, H., 2012. MicroRNA-30b-mediated regulation of catalase expression in human ARPE-19 cells. PloS one. 7, e42542.

Hayden, M.S., Ghosh, S., 2008. Shared principles in NF-kappaB signaling. Cell. 132, 344-62.

Hou, Q., Tang, J., Wang, Z., Wang, C., Chen, X., Hou, L., Dong, X.D., Tu, L., 2013. Inhibitory effect of microRNA-34a on retinal pigment epithelial cell proliferation and migration. Investigative ophthalmology & visual science. 54, 6481-8.

Hsu, S.D., Lin, F.M., Wu, W.Y., Liang, C., Huang, W.C., Chan, W.L., Tsai, W.T., Chen, G.Z., Lee, C.J., Chiu, C.M., Chien, C.H., Wu, M.C., Huang, C.Y., Tsou, A.P., Huang, H.D., 2011. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic acids research. 39, D163-9.

Hu, Z., Xie, P., Ding, Y., Yuan, D., Liu, Q., 2014. Association between variants A69S in ARMS2 gene and response to treatment of exudative AMD: a meta-analysis. The British journal of ophthalmology.

Hutchinson, J.N., Fagerness, J., Kirby, A., Reynolds, R., Zak, A., Gimelbrant, A., Plenge, R., Daly, M., Chess, A., Seddon, J.M., 2014. (Epi)Genetic analyses of age-related macular degeneration: case-control and discordant twin studies. Human heredity. 78, 59-72.

Isas, J.M., Luibl, V., Johnson, L.V., Kayed, R., Wetzel, R., Glabe, C.G., Langen, R., Chen, J., 2010. Soluble and mature amyloid fibrils in drusen deposits. Investigative ophthalmology & visual science. 51, 1304-10.

Janciauskiene, S., Krakau, T., 2001. Alzheimer's peptide: a possible link between glaucoma, exfoliation syndrome and Alzheimer's disease. Acta ophthalmologica Scandinavica. 79, 328-9.

Janelsins, M.C., Mastrangelo, M.A., Park, K.M., Sudol, K.L., Narrow, W.C., Oddo, S., LaFerla, F.M., Callahan, L.M., Federoff, H.J., Bowers, W.J., 2008. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. The American journal of pathology. 173, 1768-82.

Janssen, S.F., Gorgels, T.G.M.F., Ramdas, W.D., Klaver, C.C.W., van Duijn, C.M., Jansonius, N.M., Bergen, A.A.B., 2013. The vast complexity of primary open angle glaucoma: Disease genes, risks, molecular mechanisms and pathobiology. Progress in Retinal and Eye Research. 37, 31-67.

Janssen, S.F., Gorgels, T.G., Ten Brink, J.B., Jansonius, N.M., Bergen, A.A., 2014. Gene expression-based comparison of the human secretory neuroepithelia of the brain choroid plexus and the ocular ciliary body: potential implications for glaucoma. Fluids and barriers of the CNS. 11, 2.

Jiang, Q., Wang, Y., Hao, Y., Juan, L., Teng, M., Zhang, X., Li, M., Wang, G., Liu, Y., 2009. miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic acids research. 37, D98-104.

Johnson, L.V., Leitner, W.P., Rivest, A.J., Staples, M.K., Radeke, M.J., Anderson, D.H., 2002. The Alzheimer's A beta -peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 99, 11830-5.

Johnson, R., Noble, W., Tartaglia, G.G., Buckley, N.J., 2012. Neurodegeneration as an RNA disorder. Progress in Neurobiology. 99, 293-315.

Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M., 2014. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic acids research. 42, D199-205.

Kanemaki, N., Tchedre, K.T., Imayasu, M., Kawarai, S., Sakaguchi, M., Yoshino, A., Itoh, N., Meguro, A., Mizuki, N., 2013. Dogs and humans share a common susceptibility gene SRBD1 for glaucoma risk. PloS one. 8, e74372.

Kaplan, H.J., Leibole, M.A., Tezel, T., Ferguson, T.A., 1999. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nature medicine. 5, 292-7.

Keller, M., Ruegg, A., Werner, S., Beer, H.D., 2008. Active caspase-1 is a regulator of unconventional protein secretion. Cell. 132, 818-831.

Kim, Y., Tarallo, V., Kerur, N., Yasuma, T., Gelfand, B.D., Bastos-Carvalho, A., Hirano, Y., Yasuma, R., Mizutani, T., Fowler, B.J., Li, S., Kaneko, H., Bogdanovich, S., Ambati, B.K., Hinton, D.R., Hauswirth, W.W., Hakem, R., Wright, C., Ambati, J., 2014. DICER1/Alu RNA dysmetabolism induces Caspase-8-mediated cell death in age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 111, 16082-7.

Klein, M.L., Ferris, F.L., 3rd, Francis, P.J., Lindblad, A.S., Chew, E.Y., Hamon, S.C., Ott, J., 2010. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology. 117, 1554-9, 1559 e1.

Klein, R., Myers, C.E., Cruickshanks, K.J., Gangnon, R.E., Danforth, L.G., Sivakumaran, T.A., Iyengar, S.K., Tsai, M.Y., Klein, B.E.K., 2014. Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction and the 20-Year Cumulative Incidence of Early Age-Related Macular Degeneration The Beaver Dam Eye Study. Jama Ophthalmology. 132, 446-455.

Kleinman, M.E., Kaneko, H., Cho, W.G., Dridi, S., Fowler, B.J., Blandford, A.D., Albuquerque, R.J., Hirano, Y., Terasaki, H., Kondo, M., Fujita, T., Ambati, B.K., Tarallo, V., Gelfand, B.D., Bogdanovich, S., Baffi, J.Z., Ambati, J., 2012. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Molecular therapy : the journal of the American Society of Gene Therapy. 20, 101-8.

Kohno, H., Chen, Y., Kevany, B.M., Pearlman, E., Miyagi, M., Maeda, T., Palczewski, K., Maeda, A., 2013. Photoreceptor proteins initiate microglial activation via Toll-like receptor 4 in retinal degeneration mediated by all-trans-retinal. The Journal of biological chemistry. 288, 15326-41.

Kutty, R.K., Nagineni, C.N., Samuel, W., Vijayasarathy, C., Jaworski, C., Duncan, T., Cameron, J.E., Flemington, E.K., Hooks, J.J., Redmond, T.M., 2013. Differential regulation of microRNA-146a and microRNA-146b-5p in human retinal pigment

Kanehisa, M., Goto, S., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M., 2014. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic acids research. 42, D199-205.

Kanemaki, N., Tchedre, K.T., Imayasu, M., Kawarai, S., Sakaguchi, M., Yoshino, A., Itoh, N., Meguro, A., Mizuki, N., 2013. Dogs and humans share a common susceptibility gene SRBD1 for glaucoma risk. PloS one. 8, e74372.

Kaplan, H.J., Leibole, M.A., Tezel, T., Ferguson, T.A., 1999. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nature medicine. 5, 292-7.

Keller, M., Ruegg, A., Werner, S., Beer, H.D., 2008. Active caspase-1 is a regulator of unconventional protein secretion. Cell. 132, 818-831.

Kim, Y., Tarallo, V., Kerur, N., Yasuma, T., Gelfand, B.D., Bastos-Carvalho, A., Hirano, Y., Yasuma, R., Mizutani, T., Fowler, B.J., Li, S., Kaneko, H., Bogdanovich, S., Ambati, B.K., Hinton, D.R., Hauswirth, W.W., Hakem, R., Wright, C., Ambati, J., 2014. DICER1/Alu RNA dysmetabolism induces Caspase-8-mediated cell death in age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America. 111, 16082-7.

Klein, M.L., Ferris, F.L., 3rd, Francis, P.J., Lindblad, A.S., Chew, E.Y., Hamon, S.C., Ott, J., 2010. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology. 117, 1554-9, 1559 e1.

Klein, R., Myers, C.E., Cruickshanks, K.J., Gangnon, R.E., Danforth, L.G., Sivakumaran, T.A., Iyengar, S.K., Tsai, M.Y., Klein, B.E.K., 2014. Markers of Inflammation, Oxidative Stress, and Endothelial Dysfunction and the 20-Year Cumulative Incidence of Early Age-Related Macular Degeneration The Beaver Dam Eye Study. Jama Ophthalmology. 132, 446-455.

Kleinman, M.E., Kaneko, H., Cho, W.G., Dridi, S., Fowler, B.J., Blandford, A.D., Albuquerque, R.J., Hirano, Y., Terasaki, H., Kondo, M., Fujita, T., Ambati, B.K., Tarallo, V., Gelfand, B.D., Bogdanovich, S., Baffi, J.Z., Ambati, J., 2012. Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Molecular therapy : the journal of the American Society of Gene Therapy. 20, 101-8.

Kohno, H., Chen, Y., Kevany, B.M., Pearlman, E., Miyagi, M., Maeda, T., Palczewski, K., Maeda, A., 2013. Photoreceptor proteins initiate microglial activation via Toll-like receptor 4 in retinal degeneration mediated by all-trans-retinal. The Journal of biological chemistry. 288, 15326-41.

Kutty, R.K., Nagineni, C.N., Samuel, W., Vijayasarathy, C., Jaworski, C., Duncan, T., Cameron, J.E., Flemington, E.K., Hooks, J.J., Redmond, T.M., 2013. Differential regulation of microRNA-146a and microRNA-146b-5p in human retinal pigment

epithelial cells by interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma. Molecular vision. 19**,** 737-50.

Lambiase, A., Centofanti, M., Micera, A., Manni, G.L., Mattei, E., De Gregorio, A., de Feo, G., Bucci, M.G., Aloe, L., 1997. Nerve growth factor (NGF) reduces and NGF antibody exacerbates retinal damage induced in rabbit by experimental ocular hypertension. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 235**,** 780-5.

Leinster, V.H.L., Joy, M.T., Vuononvirta, R.E., Bolsover, S.R., Anderson, P.N., 2013. ErbB1 epidermal growth factor receptor is a valid target for reducing the effects of multiple inhibitors of axonal regeneration. Experimental Neurology. 239**,** 82-90.

Lin, H., Qian, J., Castillo, A.C., Long, B., Keyes, K.T., Chen, G., Ye, Y., 2011. Effect of miR-23 on oxidant-induced injury in human retinal pigment epithelial cells. Investigative ophthalmology & visual science. 52**,** 6308-14.

Liu, R.T., Gao, J.Y., Cao, S.J., Sandhu, N., Cui, J.Z., Chou, C.L., Fang, E., Matsubara, J.A., 2013. Inflammatory Mediators Induced by Amyloid-Beta in the Retina and RPE In Vivo: Implications for Inflammasome Activation in Age-Related Macular Degeneration. Investigative ophthalmology & visual science. 54**,** 2225-2237.

Liu, Y.H., Tian, T., 2011. Hypothesis of optineurin as a new common risk factor in normal-tension glaucoma and Alzheimer's disease. Medical Hypotheses. 77**,** 591-592.

Logue, M.W., Schu, M., Vardarajan, B.N., Farrell, J., Lunetta, K.L., Jun, G., Baldwin, C.T., Deangelis, M.M., Farrer, L.A., 2014. Search for age-related macular degeneration risk variants in Alzheimer disease genes and pathways. Neurobiology of aging. 35**,** 1510 e7-18.

London, A., Benhar, I., Schwartz, M., 2013. The retina as a window to the brain-from eye research to CNS disorders. Nature Reviews Neurology. 9**,** 44-53.

Loomis, S.J., 2014. Association of CAV1/CAV2 Genomic Variants with Primary Open-Angle Glaucoma Overall and by Gender and Pattern of Visual Field Loss (vol 121, pg 508, 2013). Ophthalmology. 121**,** 1154-1155.

Lu, H., Lu, Q., Gaddipati, S., Kasetti, R.B., Wang, W., Pasparakis, M., Kaplan, H.J., Li, Q., 2014. IKK2 inhibition attenuates laser-induced choroidal neovascularization. PloS one. 9**,** e87530.

Lu, M., Zhang, Q., Deng, M., Miao, J., Guo, Y., Gao, W., Cui, Q., 2008. An analysis of human microRNA and disease associations. PloS one. 3**,** e3420.

Lukiw, W.J., Surjyadipta, B., Dua, P., Alexandrov, P.N., 2012. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease

(AD) and in age-related macular degeneration (AMD). International journal of biochemistry and molecular biology. 3**,** 105-16.

Luna, C., Li, G., Qiu, J., Epstein, D.L., Gonzalez, P., 2011. MicroRNA-24 regulates the processing of latent TGFbeta1 during cyclic mechanical stress in human trabecular meshwork cells through direct targeting of FURIN. Journal of cellular physiology. 226**,** 1407-14.

Luna, C., Li, G., Huang, J., Qiu, J., Wu, J., Yuan, F., Epstein, D.L., Gonzalez, P., 2012. Regulation of trabecular meshwork cell contraction and intraocular pressure by miR-200c. PloS one. 7**,** e51688.

Maciotta, S., Meregalli, M., Torrente, Y., 2013. The involvement of microRNAs in neurodegenerative diseases. Frontiers in cellular neuroscience. 7**,** 265.

Makarev, E., Cantor, C., Zhavoronkov, A., Buzdin, A., Aliper, A., Csoka, A.B., 2014. Pathway activation profiling reveals new insights into Age-related Macular Degeneration and provides avenues for therapeutic interventions. Aging-Us. 6**,** 1064-1075.

Medeiros, N.E., Curcio, C.A., 2001. Preservation of ganglion cell layer neurons in age-related macular degeneration. Investigative ophthalmology & visual science. 42**,** 795-803.

Medzhitov, R., 2008. Origin and physiological roles of inflammation. Nature. 454**,** 428-35.

Nag, A., Venturini, C., Small, K.S., Young, T.L., Viswanathan, A.C., Mackey, D.A., Hysi, P.G., Hammond, C., 2014. A genome-wide association study of intra-ocular pressure suggests a novel association in the gene FAM125B in the TwinsUK cohort. Human molecular genetics. 23**,** 3343-8.

Nagineni, C.N., Kommineni, V.K., William, A., Detrick, B., Hooks, J.J., 2012. Regulation of VEGF Expression in Human Retinal Cells by Cytokines: Implications for the Role of Inflammation in Age-Related Macular Degeneration. Journal of cellular physiology. 227**,** 116-126.

Normando, E.M., Turner, L.A., Cordeiro, M.F., 2013. The potential of annexin-labelling for the diagnosis and follow-up of glaucoma. Cell and tissue research. 353**,** 279-85.

Ogunshola, O.O., Antoniou, X., 2009. Contribution of hypoxia to Alzheimer's disease: is HIF-1alpha a mediator of neurodegeneration? Cellular and molecular life sciences : CMLS. 66**,** 3555-63.

Ojha, P., Wiggs, J.L., Pasquale, L.R., 2013. The genetics of intraocular pressure. Seminars in ophthalmology. 28**,** 301-5.

Ozel, A.B., Moroi, S.E., Reed, D.M., Nika, M., Schmidt, C.M., Akbari, S., Scott, K., Rozsa, F., Pawar, H., Musch, D.C., Lichter, P.R., Gaasterland, D., Branham, K., Gilbert, J., Garnai, S.J., Chen, W., Othman, M., Heckenlively, J., Swaroop, A., Abecasis, G., Friedman, D.S., Zack, D., Ashley-Koch, A., Ulmer, M., Kang, J.H., Liu, Y., Yaspan, B.L., Haines, J., Allingham, R.R., Hauser, M.A., Pasquale, L., Wiggs, J., Richards, J.E., Li, J.Z., 2014. Genome-wide association study and meta-analysis of intraocular pressure. Human genetics. 133, 41-57.

Paylakhi, S.H., Yazdani, S., April, C., Fan, J.B., Moazzeni, H., Ronaghi, M., Elahi, E., 2012. Non-housekeeping genes expressed in human trabecular meshwork cell cultures. Molecular vision. 18, 241-54.

Paylakhi, S.H., Moazzeni, H., Yazdani, S., Rassouli, P., Arefian, E., Jaberi, E., Arash, E.H., Gilani, A.S., Fan, J.B., April, C., Amin, S., Suri, F., Elahi, E., 2013. FOXC1 in human trabecular meshwork cells is involved in regulatory pathway that includes miR-204, MEIS2, and ITGbeta1. Experimental eye research. 111, 112-21.

Plantner, J.J., Jiang, C., Smine, A., 1998. Increase in interphotoreceptor matrix gelatinase A (MMP-2) associated with age-related macular degeneration. Experimental eye research. 67, 637-645.

Pocock, J.M., Liddle, A.C., 2001. Microglial signalling cascades in neurodegenerative disease. Progress in brain research. 132, 555-65.

Qu, J., Wang, D., Grosskreutz, C.L., 2010. Mechanisms of retinal ganglion cell injury and defense in glaucoma. Experimental eye research. 91, 48-53.

Reczko, M., Maragkakis, M., Alexiou, P., Grosse, I., Hatzigeorgiou, A.G., 2012. Functional microRNA targets in protein coding sequences. Bioinformatics. 28, 771-6.

Restrepo, N.A., Spencer, K.L., Goodloe, R., Garrett, T.A., Heiss, G., Buzkova, P., Jorgensen, N., Jensen, R.A., Matise, T.C., Hindorff, L.A., Klein, B.E., Klein, R., Wong, T.Y., Cheng, C.Y., Cornes, B.K., Tai, E.S., Ritchie, M.D., Haines, J.L., Crawford, D.C., 2014. Genetic determinants of age-related macular degeneration in diverse populations from the PAGE study. Investigative ophthalmology & visual science. 55, 6839-50.

Roberti, G., Mantelli, F., Macchi, I., Massaro-Giordano, M., Centofanti, M., 2014. Nerve growth factor modulation of retinal ganglion cell physiology. Journal of cellular physiology. 229, 1130-3.

Rodriguez Diez, G., Sanchez Campos, S., Giusto, N.M., Salvador, G.A., 2013. Specific roles for Group V secretory PLA(2) in retinal iron-induced oxidative stress. Implications for age-related macular degeneration. Experimental eye research. 113, 172-81.

Sabatel, C., Malvaux, L., Bovy, N., Deroanne, C., Lambert, V., Gonzalez, M.L., Colige, A., Rakic, J.M., Noel, A., Martial, J.A., Struman, I., 2011. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PloS one. 6, e16979.

Sakurai, M., Higashide, T., Ohkubo, S., Takeda, H., Sugiyama, K., 2014. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension. The British journal of ophthalmology. 98, 469-73.

Schwartz, M., Belkin, M., Yoles, E., Solomon, A., 1996. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. Journal of glaucoma. 5, 427-32.

Seddon, J.M., Reynolds, R., Yu, Y., Rosner, B., 2014. Three new genetic loci (R1210C in CFH, variants in COL8A1 and RAD51B) are independently related to progression to advanced macular degeneration. PloS one. 9, e87047.

Shen, J., Yang, X., Xie, B., Chen, Y., Swaim, M., Hackett, S.F., Campochiaro, P.A., 2008. MicroRNAs regulate ocular neovascularization. Molecular therapy : the journal of the American Society of Gene Therapy. 16, 1208-16.

Shen, W., Lee, S.R., Araujo, J., Chung, S.H., Zhu, L., Gillies, M.C., 2014. Effect of glucocorticoids on neuronal and vascular pathology in a transgenic model of selective Muller cell ablation. Glia. 62, 1110-24.

Sivak, J.M., 2013. The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease. Investigative ophthalmology & visual science. 54, 871-880.

Sposato, V., Parisi, V., Manni, L., Antonucci, M.T., Di Fausto, V., Sornelli, F., Aloe, L., 2009. Glaucoma alters the expression of NGF and NGF receptors in visual cortex and geniculate nucleus of rats: effect of eye NGF application. Vision research. 49, 54-63.

Steen, B., Sejersen, S., Berglin, L., Seregard, S., Kvanta, A., 1998. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Investigative ophthalmology & visual science. 39, 2194-200.

Stone, E.M., Braun, T.A., Russell, S.R., Kuehn, M.H., Lotery, A.J., Moore, P.A., Eastman, C.G., Casavant, T.L., Sheffield, V.C., 2004. Missense variations in the fibulin 5 gene and age-related macular degeneration. New England Journal of Medicine. 351, 346-353.

Surgucheva, I., Chidambaram, K., Willoughby, D.A., Surguchov, A., 2010. Matrix metalloproteinase 9 expression: new regulatory elements. Journal of ocular biology, diseases, and informatics. 3, 41-52.

Takeuchi, O., Akira, S., 2010. Pattern Recognition Receptors and Inflammation. Cell. 140, 805-820.

Tanaka, Y., Tsuda, S., Kunikata, H., Sato, J., Kokubun, T., Yasuda, M., Nishiguchi, K.M., Inada, T., Nakazawa, T., 2014. Profiles of extracellular miRNAs in the aqueous humor of glaucoma patients assessed with a microarray system. Scientific reports. 4, 5089.

Tang, S.C., Lathia, J.D., Selvaraj, P.K., Jo, D.G., Mughal, M.R., Cheng, A., Siler, D.A., Markesbery, W.R., Arumugam, T.V., Mattson, M.P., 2008. Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Experimental Neurology. 213, 114-121.

Tezel, G., Wax, M.B., 2004. Hypoxia-inducible factor 1alpha in the glaucomatous retina and optic nerve head. Archives of ophthalmology. 122, 1348-56.

Tezel, G., 2008. TNF-alpha signaling in glaucomatous neurodegeneration. Glaucoma: An Open Window to Neurodegeneration and Neuroprotection. 173, 409-421.

Tilstra, J.S., Clauson, C.L., Niedernhofer, L.J., Robbins, P.D., 2011. NF-kappaB in Aging and Disease. Aging and disease. 2, 449-65.

Tsai, N.P., Tsui, Y.C., Pintar, J.E., Loh, H.H., Wei, L.N., 2010. Kappa opioid receptor contributes to EGF-stimulated neurite extension in development. Proceedings of the National Academy of Sciences of the United States of America. 107, 3216-21.

Tseng, W.A., Thein, T., Kinnunen, K., Lashkari, K., Gregory, M.S., D'Amore, P.A., Ksander, B.R., 2013. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration. Investigative ophthalmology & visual science. 54, 110-20.

Unterlauft, J.D., Claudepierre, T., Schmidt, M., Muller, K., Yafai, Y., Wiedemann, P., Reichenbach, A., Eichler, W., 2014. Enhanced survival of retinal ganglion cells is mediated by Muller glial cell-derived PEDF. Experimental eye research. 127, 206-14.

van Noort, J.M., Bsibsi, M., 2009. Toll-like receptors in the CNS: implications for neurodegeneration and repair. Neurotherapy: Progress in Restorative Neuroscience and Neurology. 175, 139-148.

Vandooren, J., Van Damme, J., Opdenakker, G., 2014. On the structure and functions of gelatinase B/matrix metalloproteinase-9 in neuroinflammation. Progress in brain research. 214, 193-206.

Vlachos, I.S., Kostoulas, N., Vergoulis, T., Georgakilas, G., Reczko, M., Maragkakis, M., Paraskevopoulou, M.D., Prionidis, K., Dalamagas, T., Hatzigeorgiou, A.G., 2012.

DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic acids research. 40, W498-504.

Vukic, V., Callaghan, D., Walker, D., Lue, L.F., Liu, Q.Y., Couraud, P.O., Romero, I.A., Weksler, B., Stanimirovic, D.B., Zhang, W.D., 2009. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiology of Disease. 34, 95-106.

Walter, S., Letiembre, M., Liu, Y., Heine, H., Penke, B., Hao, W., Bode, B., Manietta, N., Walter, J., Schulz-Schaffer, W., Fassbender, K., 2007. Role of the toll-like receptor 4 in neuro-inflammation in Alzheimer's disease. Cellular Physiology and Biochemistry. 20, 947-956.

Wang, D., Weng, Q., Zhang, L., He, Q., Yang, B., 2009. VEGF and Bcl-2 interact via MAPKs signaling pathway in the response to hypoxia in neuroblastoma. Cellular and molecular neurobiology. 29, 391-401.

Weidemann, A., Johnson, R.S., 2008. Biology of HIF-1alpha. Cell death and differentiation. 15, 621-7.

Yang, X., Luo, C., Cai, J., Powell, D.W., Yu, D., Kuehn, M.H., Tezel, G., 2011. Neurodegenerative and inflammatory pathway components linked to TNF-alpha/TNFR1 signaling in the glaucomatous human retina. Investigative ophthalmology & visual science. 52, 8442-54.

Yee Koh, M., Spivak-Kroizman, T.R., Powis, G., 2008. HIF-1 regulation: not so easy come, easy go. Trends in biochemical sciences. 33, 526-34.

Yin, H.B., Chen, L., Chen, X.M., Liu, X.Y., 2008. Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma. Medical Hypotheses. 71, 77-80.

Yoneda, S., Hara, H., Hirata, A., Fukushima, M., Inomata, Y., Tanihara, H., 2005. Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Japanese journal of ophthalmology. 49, 106-8.

Yoon, C., Kim, D., Kim, S., Park, G.B., Hur, D.Y., Yang, J.W., Park, S.G., Kim, Y.S., 2014. MiR-9 regulates the post-transcriptional level of VEGF165a by targeting SRPK-1 in ARPE-19 cells. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 252, 1369-76.

Yuan, J., Yankner, B.A., 2000. Apoptosis in the nervous system. Nature. 407, 802-9.

CHAPTER II

RETINAL MIRNA EXPRESSION ON AMYLOID-B-INDUCED AGE-RELATED MACULAR DEGENERATION IN RAT: A TRANSLATIONAL STUDY

Giovanni Luca Romano[1], Chiara Bianca Maria Platania[1], Filippo Drago[1], Marco Ragusa[2], Cristina Barbagallo[2], Cinzia Di Pietro[2], Michele Purrello[2], Michele Reibaldi[3], Teresio Avitabile[3], Antonio Longo[3] and Claudio Bucolo[1]

[1]Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Catania, Italy;

[2]Department of Biomedical and Biotechnological Sciences, Section of Biology and Genetics G Sichel, BioMolecular, Genome and Complex Systems BioMedicine Unit (BMGS), University of Catania, Catania, Italy;

[3]Department of Ophthalmology, School of Medicine, University of Catania, Catania, Italy.

Abstract

Age related macular degeneration (AMD) is the leading cause of blindness among people aged 50 and over. Retinal deposition of amyloid-β (Aβ) aggregates in AMD patients has suggested a potential link between AMD and Alzheimer's disease (AD). We have evaluated the differential retinal expression profile of miRNAs in a rat model of AMD elicited by Aβ. A serum profile of miRNAs in AMD patients has been also assessed using single TaqMan assay. Analysis of rat retina revealed that miR-27a, miR-146a and miR-155 are up-regulated in comparison to control rats. Seven miRNA (miR-9, miR-23a, miR-27a, miR-34a, miR-126, miR-146a and miR-155) have been found to be dysregulated in serum of AMD patients in comparison to control group. Analysis of pathways has revealed that dysregulated miRNAs, both in the AMD animal model and in AMD patients, can target genes regulating pathways linked to neurodegeneration and inflammation, reinforcing the hypothesis that AMD is a protein misfolding disease such as AD. In fact, miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 have been found to be dysregulated both in AMD and AD. In conclusion, we suggest that miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 represent potential biomarkers and new pharmacological targets for AMD.

Keywords: age related macular degeneration, Alzheimer's disease, amyloid beta, miRNA

Introduction

Age related macular degeneration (AMD) is a common eye disease and the leading cause of blindness among people age 50 and older. AMD exists in two forms; the dry and the wet. Dry AMD is characterized by cellular debris, identified as drusen bodies, that accumulate between the choroid and retina. The wet form bears abnormal growth of choroidal blood vessels leading to detachment of retina along with vascular leakage and related retinal edema. AMD is listed by the WHO among the "priority eye disease". Besides a series of phase II/III clinical trials, up to now there is no approved treatment for dry AMD, and treatment for wet AMD is not definitive. Wet AMD patients in general experience rapid visual aberration with progression of the disease, due to vascular leakage; whereas dry AMD is often asymptomatic [1,2]. Therefore, validated microinvasive biomarkers of AMD are mandatory in order to prevent irreversible macular damage. Several SNPs and their association to AMD were investigated and validated: such SNPs involve complement proteins [3]. Furthermore, inflammation is a response to molecules coming from dysfunctional retinal pigment epithelium (RPE), such as lipofuscin, β-amyloid, carboxyethyl pyrrole and ocular inflammatory processes that were recognized as hallmark of AMD [4,5]. Along to these molecules found in drusen of AMD patients, C-reactive protein was found in serum of patients with severe AMD [6-8]; however, other studies have not confirmed the detection of C-reactive protein in serum of AMD patients [9,10]. Therefore, the identification and validation of serum, minimally-invasive, biomarkers of AMD are still challenging. In this perspective, differential expression of miRNAs in serum or plasma is a potential approach for identification of novel biomarkers of AMD. MiRNAs are small, approximately 22 nucleotides, non-coding RNA molecules with important regulatory functions, i.e. post-transcriptional regulation of gene expression [11]. Cells can secrete miRNAs that can be found stably in serum, plasma and many other biological fluids [12,13]. Extracellular miRNAs are stable due to association to cell-derived nanovesicles (e.g., exosomes), RNA-binding proteins (e.g. Argonaute 2) or high density lipoproteins HDL [14]. Recently, Mènard al. (2016) [15] profiled miRNAs in vitreous and plasma of exudative AMD patients, by means of non-biased miRNA arrays and validation with qPCR; the authors found that miRNA-146a was significantly up-regulated both in vitreous and plasma of AMD patients [15]. Interestingly, dysregulation of miRNA-146a was found also in Alzheimer's disease (AD), i.e. down-regulation in cerebrospinal fluid (CSF) of AD patients [16-18]. AMD is a complex multifactorial disease and a pathogenic mechanism common to AD was postulated on the basis of Aβ deposition in drusen of AMD patients [5,19-22].

The aim of the present study was to discover new insights in the pathogenic mechanisms of AMD co-shared with AD, and to identify putative biomarkers of AMD along with novel pharmacological targets.

Results

Dysregulation of miRNAs in AMD model

We have analyzed the expression of 13 miRNAs (Table 1), in retina extracts of Sprague Dawley rats subjected to intravitreal injection (IVT) of hAβ1-42 oligomers. This in vivo model of AMD has been used on the basis of previous reports about the presence of hAβ1-42 deposition in drusen bodies of AMD patients [6-8,22]. Intravitreal injection of hAβ1-42 has induced the up-regulation of three miRNAs: miR-27a, miR-146a and miR-155 (Table 2 and Fig. 1). Furthermore, we have investigated the differential expression of miRNAs in the serum of Aβ-injected rats (Aβ ITV) and we have found that miR-155 was downregulated in Aβ ITV group in comparison to control group (FC -4.76; pvalue t-test: 0.029).

Results from the in vivo model of AMD, elicited by intravitreal injection of Aβ oligomers, can give hints about early events due to retinal Aβ deposition; therefore, we have looked to dysregulation of miRNAs that would persist with progression of AMD.

Dysregulation of miRNAs in patients with AMD

In this perspective, we have analyzed the 13 miRNAs also in serum of AMD patients (Table 3). Dysregulation of 7 miRNAs (Table 3 and Fig. 1), out of 13 tested, has been found in serum of AMD patients in comparison to serum of control group. In particular, we observed the upregulation of miR-9, miR-23a, miR-27a, miR-34a, miR-126 and miR-146a in serum of AMD patients; on the contrary miR-155 was down-regulated in serum, similarly to serum of rats subjected to intravitreal injection of Aβ. Table 3 shows data about the expression profile of 13 miRNAs in serum of AMD patients. Figure 2 reports box-plots of six miRNAs associated both to AMD and AD.

Bioinformatic analysis of biochemical pathways associated to miRNAs

Biochemical pathways potentially regulated by miRNAs differentially expressed in retina of Aβ-injected rats (Fig. 3 and Table 4a) and in serum of AMD patients (Fig. 4 and Table 4b) have been identified accessing to the web server DIANA-miRPath v.3. The miR-27a, miR-146a and miR-155 (Fig. 3 and Table 4a), which are up-regulated in retina of Aβ injected rats, can regulate the top scored "TGF-β" (p-value 1×10^{-11}) and "prion diseases"

(p-value 2×10^{-11}) pathways, along with inflammatory pathways (mTOR, TNFα, HIF signaling, NF-kB) [5]. Interestingly, apoptosis (p-value 0.004), PI3K-AKT (p-value 0.01) and p53 pathways (p-value 0.02) can be regulated by miRNAs differentially expressed in the retina of AMD animal model. These results confirm our previous data [22], where a deficit of TGF-β signaling in Aβ injected rats was counteracted by TGF-β1 coadministration. Furthermore, regulation of "prion diseases" pathway by miR-27a, miR-146a and miR-155, suggests that AMD can be a conformational disease due to deposition of Aβ oligomers in drusen bodies, strengthening the link with AD. The potential link to AD is recalled also by the deregulation of insulin receptor signaling [23-27]. The set of miRNAs differentially expressed in AMD patients can regulate the same pathways of miRNAs deregulated in the animal model of AMD (Fig. 4 and Table 4b). In fact, in AMD patients the TGF-β (p-value 4×10^{-7}) and "prion diseases" (p-value 1×10^{-6}) pathways have been also top scored, along to lipid metabolism, neurodegenerative and inflammatory pathways. Interestingly, the VEGF pathway (p-value 0.03) has been targeted only by the set of miRNAs deregulated in serum of AMD patients.

Analysis of serum of Aβ injected rats has revealed that one miRNA, out of 13, miR-155 is downregulated in comparison to control rats, similarly to what has been found in serum of AMD patients.

We have looked to pathways that can be regulated by miR-155 (Table 4c). Genes involved in the TGF-β signaling pathway are targets of miR-155 (p-value 0.0004), additionally, miR-155 can regulate the apoptosis pathway (p-value 0.001) and several inflammatory pathways, that are also regulated by the set of miRNAs differentially expressed both in Aβ injected rats and in AMD patients.

Discussion

Thirteen miRNAs (Table 1) have been selected on the basis of previous reports based on their role in AD and AMD. Analysis of these 13 miRNAs revealed that 7 miRNAs showed a significant upregulation in serum of AMD patients in comparison to control group (miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 and miR-126). Three miRNAs have been also deregulated both in AMD patients and in retina of Aβ injected rats (miR-27a, miR-146a, miR-155). In accordance to the finding of Mènard et al (2016) [15], we have found that miR-146a is up-regulated in plasma of AMD patients, in retina of Aβ injected rats and it is dysregulated also in AD patients [15-18]. To our knowledge, dysregulation of miR-27a has not been reported by other authors before the study hereby presented, neither in

experimental animal models nor in in vitro models of AMD. The potential role of miR-27a in AMD was suggested for the first time by Wang S. and co-authors (2012) [28] and involvement of miR-27 in AD was documented by Maes et al. (2009) and Sala Frigerio et al. (2013) [29,30]. We have found down-regulation of miR-155 in plasma of AMD patients and Aβ injected rats; whereas we have found up-regulation of miR-155 in retina of Aβ injected rats, along with miR-27a and miR-146a. Our result is in accordance to the report of Guedes and coauthors (2014) [31]. In this report, miR-155 was up-regulated in hippocampal and cortical brain regions of 3-Tg AD animal; furthermore miR-155 was up-regulated in microglia and astrocytes cultures treated with Aβ oligomers. Additionally, miR-155 was found to negatively affect the blood brain barrier function [32], thus the up-regulation of miR-155 in retina of rats injected with Aβ oligomers might influence also the integrity of the blood retinal barrier (BRB). Indeed, retinal upregulation of miR-27a, miR-146a and miR-155 has strengthen the validity of the animal model of AMD induced by intravitreal injection of Aβ oligomers [22]; furthermore this result sustains the result in human serum, supporting the hypothesis of a narrow link between AMD and AD. With exception of miRNA-155 down-regulated in serum of AMD patients and in serum of Aβ injected rats, six miRNAs (miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-126) showed an upregulation in serum of AMD patients. Lack of differentially expressed circulating miRNAs in serum of Aβ injected rats, other than down-regulated miR-155, can be explained by the variables that characterize miRNA secretion (e.g. aging, duration and type of pathology) [14,33].

In order to study the biological role of the miRNAs dysregulated in retina of Aβ injected rats and in serum of AMD patients, we have predicted the combinatorial effects of miRNAs in regulation of biological relevant pathways by means of DIANA-miRPath v.3. Given miRNAs as input, DianamiRPath gives as output the KEGG (Kyoto Encyclopedia of Genes and Genomes) pathways potentially regulated by genes targeted by input miRNAs. We have found that miRNAs, deregulated both in serum of AMD patients and retina of Aβ injected rats, can regulate pathways associated to neurodegenerative diseases (e.g. apoptosis, ubiquitin proteolysis, neurotrophin signaling) along to inflammatory signaling pathways (e.g. mTOR, HIF, TNFα and VEGF signaling) (Figs 3 and 4). Furthermore, TGF-β signaling has been one of the top scored pathways along with "prion diseases" pathway. Deregulation of TGF-β pathway in AD and protection of TGF-β1 toward brain neuroinflammatory process was previously reported [34-37] and TGF-β1 administration reverted the Bax/Bcl2 ratio in retina of Aβ injected rats [22].

Indeed, we postulate that Aβ retinal deposition leads to inflammatory and apoptotic events along with differential expression of miRNAs able to target genes, that in turn de-regulate the TGF-β pathway. In fact, miR-155 and miR-27a target 42 genes involved in the TGF-β pathway (DIANAmiRPath), whereas miR-146a could target genes involved in inflammatory pathways (Toll-like receptor, NF-kappa B, TNF signaling pathways).

Furthermore, analysis of pathways, associated to miRNAs deregulated in serum of AMD patients and in retina of Aβ injected rats, has revealed three recurring pathways "prion diseases", "TGF-beta signaling" and "insulin receptor signaling" KEGG pathways, reinforcing the hypothesis of a narrow link between AMD and AD. It is worth of note that miRNAs deregulated both in AMD patients and in rats with amyloid-β-induced AMD are able to target the TGF-β signaling pathway leading to a putative impairment of Smad-dependent TGF-β1 signaling [22,38,39]. In conclusion, our results suggest that miR-27a, miR-146a and miR-155 might be up-regulated due to Aβ deposition in drusen bodies, in the retina of AMD patients, leading to inflammatory and neurodegenerative events; the progression of AMD can be characterized by secretion of circulating miRNAs associated to Alzheimer's disease (miR-9, miR-23a, miR-27a, miR-34a, miR-126, miR-146a, miR-155) that regulate genes involved in neurodegenerative and inflammatory pathways. However, our results do not clarify which is the primum movens that cause the deposition of Aβ oligomers[5].

Up-regulation of miR-27a and miR-146a, and down-regulation of miR-155 can be potential biomarkers of early AMD, however further studies are needed to confirm this hypothesis, because modulation of miRNAs is influenced by several factors [14,33]. In conclusion we suggest that miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 represent potential biomarkers and new pharmacological targets for AMD.

Methods

Literature search and selection of microRNAs to be analyzed

Extensive literature search has been carried out in order to select miRNAs (Table 1) similarly dysregulated in AMD and AD. Dysregulation of miRNAs in AMD and AD has been evaluated accessing to miR2Disease and Human microRNA Disease Database (HMDD) databases and through literature search 5.

AMD model

Fresh human Aβ(1–42) (hAβ1-42) oligomers have been prepared accordingly to the following protocol:

• purchasing of lyophilized hAβ1-42 trifluoroacetic salt by Invitrogen©, catalog n° 03-112;

• reconstitution of peptide at a concentration 1 mM in 100% 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP);

• incubation of solution at room temperature for 1 hour and then sonication for 10 minutes in water bath sonicator;

• removing of HIFP under gentle stream of Argon;

• storage: vials, containing peptide Parafilm©-sealed at -20 °C;

• reconstitution of peptide film with anhydrous dimethyl-sulfoxide (DMSO) added at final hAβ1-42 concentration 5 mM;

• dilution with sterile PBS pH 7.4, final [hAβ1-42]=100 uM, and incubation for 24 h at 4°C.

This protocol is in accordance to the protocol used by several groups 40-43 and to the original protocol developed by Klein and co-authors (2001) 44.

Male Sprague-Dawley rats (250-300 g) have been purchased from Harlan (Udine, Italy). Animal procedures were approved by the Institutional Animal Care and Use Committee of the Catania University, and were in accordance with the guidelines of ARVO (Association for Research in Vision and Ophthalmology) Statement for the Use of Animals in Ophthalmic and Vision Research. The animals have been fed on standard laboratory food and allowed free access to water in an air controlled room with a 12-h light/12-h dark cycle. The animals have been randomly divided in two experimental groups: 1) control group: received intravitreal injection of 2 μl of sterile PBS pH 7.2, DMSO 2%; 2) treated group received intravitreal injection of 0.2nmol of Aβ (2 μl of Aβ oligomers solution). Animals have been anesthetized by intravenous injection of 5 mg/kg agent (2.5 mg/kg tiletamine•HCl, and 2.5 mg/kg zolazepam•HCl; Zoletil, Virbac, Italy) and 1 drop of local anesthetic (oxybuprocaine 0.4%; Novesina, Novartis, Italy) has been administered to the eye, prior intravitreal injection 22. After 72 h the animals were killed and blood and retina samples collected.

Clinical study

This study has been conducted accordingly to the Declaration of Helsinki and we have obtained from all patients the informed consent after explanation of the nature and possible

consequences of the study. Eleven patients (average age = 50) have been enrolled between May 2014 and July 2014 at the Retina Division of the Eye Institute of the University of Catania (Italy); active choroidal neovascularization (CNV) secondary to neovascular AMD has been confirmed in patients by fluorescein angiography. We have applied the following exclusion criteria: active uveitis or ocular infection, presence of any retinopathy other than AMD, and any ocular surgery within the 60 days prior to enrollment. We have excluded also patients with cardiovascular disease, including a history of stroke or myocardial infarction less than 3 months prior to screening, or an uncontrolled blood pressure defined as systolic value of >160 mmHg or diastolic value of >100 mmHg at screening, patients with diabetes mellitus, and patients with a history of cancer. For each patient with neovascular AMD, a healthy subject has been enrolled from our general outpatient department, in order to serve as control; the healthy subject has matched the AMD patient in terms of age and sex, fulfilling the inclusion and exclusion criteria. All enrolled subjects have underwent fasting venous blood sampling. Blood samples have been obtained by vein puncture using sterile and dry vacutainer tubes (BD Biosciences, Italy). Samples have been centrifuged for serum isolation within 2 h from withdrawal. Whole blood was incubated for 30 min at 20°C before being centrifuged at 3000 rpm for 15 min at 4°C. Serum was divided into aliquots and stored at -80°C until analysis.

RNA isolation from serum and retina
Serum samples have been centrifuged at 2000 rpm for 10' to pellet any circulating cells or debris. MiRNAs have been extracted from 400 μl of serum samples by using Qiagen miRNeasy mini kit (Qiagen, GmbH, Hilden, Germany), according to Qiagen supplementary protocol for purification of small RNAs from serum and plasma, and finally eluted in 40 μl of elution buffer. Total RNA, from retina samples, has been purified by using TRIzol® reagent (ThermoFisher Scientific), accordingly to the manufacturer's instructions. Quantification of RNAs has been performed by fluorometry and spectrophotometry.

miRNA profiling by TaqMan assays
We have carried out RNA retro-transcription by of TaqMan® MicroRNA Reverse Transcription Kit (ThermoFisher Scientific); amplification has been performed by Real Time PCR with TaqMan probes (ThermoFisher Scientific), accordingly to the manufacturer's instructions. We have used miR-320a as reference gene for normalization of human serum samples, and U6 and miR-16 for rat samples. Real Time PCRs have been

carried out on a 7900 HT Fast Real Time PCR System (Applied Biosystem│Life Technologies TM Monza, Italy).

Analysis of miRNAs expression data and statistical analysis

Expression fold changes have been calculated by the 2-ΔΔCt method 45.We have considered statistically differentially expressed miRNAs given a p-value <0.05, after analysis of ΔCts of pathological and normal samples by t-test.

Bioinformatic analysis of biochemical pathways

The probability of association between miRNAs and KEGG pathways, was calculated accessing to the web server DIANA-miRPath 3.0 5, using the miRtarbase v7 algorithm. The following groups of miRNAs were analyzed:

a) miR-27a, miR-146a, miR-155

b) miR-9, miR-23a, miR-27a, miR-34a, miR-126,miR-146a, miR-155

c) miR-155

References

1. Yorston, D. What's new in age-related macular degeneration? Community Eye Health 19, 4-5 (2006).

2. Pascolini, D. & Mariotti, S. P. Global estimates of visual impairment: 2010. Br J Ophthalmol 96, 614-618, doi:10.1136/bjophthalmol-2011-300539 (2012).

3. Gemenetzi, M. & Lotery, A. J. Complement pathway biomarkers and age-related macular degeneration. Eye (Lond) 30, 1-14, doi:10.1038/eye.2015.203 (2016).

4. Stanton, C. M. & Wright, A. F. Inflammatory biomarkers for AMD. Adv Exp Med Biol 801, 251-257, doi:10.1007/978-1-4614-3209-8_32 (2014).

5. Romano, G. L. et al. MicroRNA target prediction in glaucoma. Prog Brain Res 220, 217- 240, doi:10.1016/bs.pbr.2015.04.013 (2015).

6. Seddon, J. M., Gensler, G., Milton, R. C., Klein, M. L. & Rifai, N. Association between Creactive protein and age-related macular degeneration. JAMA 291, 704-710, doi:10.1001/jama.291.6.704 (2004).

7. Seddon, J. M., Gensler, G. & Rosner, B. C-reactive protein and CFH, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology 117, 1560-1566, doi:10.1016/j.ophtha.2009.11.020 (2010).

8. Vine, A. K., Stader, J., Branham, K., Musch, D. C. & Swaroop, A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 112, 2076-2080, doi:10.1016/j.ophtha.2005.07.004 (2005).

9. Dasch, B. et al. Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. Arch Ophthalmol 123, 1501-1506, doi:10.1001/archopht.123.11.1501 (2005).

10. McGwin, G., Hall, T. A., Xie, A. & Owsley, C. The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br J Ophthalmol 89, 1166-1170, doi:10.1136/bjo.2005.067397 (2005).

11. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).

12. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105, 10513-10518, doi:10.1073/pnas.0804549105 (2008).

13. Weber, J. A. et al. The microRNA spectrum in 12 body fluids. Clin Chem 56, 1733-1741, doi:10.1373/clinchem.2010.147405 (2010).

14. Creemers, E. E., Tijsen, A. J. & Pinto, Y. M. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 110, 483-495, doi:10.1161/CIRCRESAHA.111.247452 (2012).

15. Menard, C. et al. MicroRNA signatures in vitreous humour and plasma of patients with exudative AMD. Oncotarget, doi:10.18632/oncotarget.8280 (2016).

16. Kiko, T. et al. MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J Alzheimers Dis 39, 253-259, doi:10.3233/JAD-130932 (2014).

17. Muller, M., Kuiperij, H. B., Claassen, J. A., Kusters, B. & Verbeek, M. M. MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiol Aging 35, 152-158, doi:10.1016/j.neurobiolaging.2013.07.005 (2014).

18. Denk, J. et al. MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease. PLoS One 10, e0126423, doi:10.1371/journal.pone.0126423 (2015).

19. Dentchev, T., Milam, A. H., Lee, V. M., Trojanowski, J. Q. & Dunaief, J. L. Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 9, 184-190 (2003).

20. Isas, J. M. et al. Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 51, 1304-1310, doi:10.1167/iovs.09-4207 (2010).

21. Johnson, L. V., Leitner, W. P., Staples, M. K. & Anderson, D. H. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 73, 887-896, doi:10.1006/exer.2001.1094 (2001).

22. Fisichella, V. et al. TGF-beta1 prevents rat retinal insult induced by amyloid-beta (1-42) oligomers. Eur J Pharmacol, doi:10.1016/j.ejphar.2016.02.002 (2016).

23. Giuffrida, M. L. et al. Beta-amyloid monomer and insulin/IGF-1 signaling in Alzheimer's disease. Mol Neurobiol 46, 605-613, doi:10.1007/s12035-012-8313-6 (2012).

24. Sajan, M. et al. Brain Insulin Signaling Is Increased in Insulin-Resistant States and Decreases in FOXOs and PGC-1alpha and Increases in Abeta1-40/42 and

Phospho-Tau May Abet Alzheimer Development. Diabetes 65, 1892-1903, doi:10.2337/db15-1428 (2016).

25. Gontier, G., George, C., Chaker, Z., Holzenberger, M. & Aid, S. Blocking IGF Signaling in Adult Neurons Alleviates Alzheimer's Disease Pathology through Amyloid-beta Clearance. J Neurosci 35, 11500-11513, doi:10.1523/JNEUROSCI.0343-15.2015 (2015).

26. Takach, O., Gill, T. B. & Silverman, M. A. Modulation of insulin signaling rescues BDNF transport defects independent of tau in amyloid-beta oligomer-treated hippocampal neurons. Neurobiol Aging 36, 1378-1382, doi:10.1016/j.neurobiolaging.2014.11.018 (2015).

27. Han, X. et al. Insulin Attenuates Beta-Amyloid-Associated Insulin/Akt/EAAT Signaling Perturbations in Human Astrocytes. Cell Mol Neurobiol 36, 851-864, doi:10.1007/s10571- 015-0268-5 (2016).

28. Wang, S., Koster, K. M., He, Y. & Zhou, Q. miRNAs as potential therapeutic targets for age-related macular degeneration. Future Med Chem 4, 277-287, doi:10.4155/fmc.11.176 (2012).

29. Maes, O. C., Chertkow, H. M., Wang, E. & Schipper, H. M. MicroRNA: Implications for Alzheimer Disease and other Human CNS Disorders. Curr Genomics 10, 154-168, doi:10.2174/138920209788185252 (2009).

30. Sala Frigerio, C. et al. Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology 81, 2103-2106, doi:10.1212/01.wnl.0000437306.37850.22 (2013).

31. Guedes, J. R. et al. Early miR-155 upregulation contributes to neuroinflammation in Alzheimer's disease triple transgenic mouse model. Hum Mol Genet 23, 6286-6301, doi:10.1093/hmg/ddu348 (2014).

32. Lopez-Ramirez, M. A. et al. MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation. FASEB J 28, 2551-2565, doi:10.1096/fj.13-248880 (2014).

33. Weilner, S., Schraml, E., Redl, H., Grillari-Voglauer, R. & Grillari, J. Secretion of microvesicular miRNAs in cellular and organismal aging. Exp Gerontol 48, 626-633, doi:10.1016/j.exger.2012.11.017 (2013).

34. Caraci, F. et al. TGF-beta 1 protects against Abeta-neurotoxicity via the phosphatidylinositol-3-kinase pathway. Neurobiol Dis 30, 234-242, doi:10.1016/j.nbd.2008.01.007 (2008).

35. Caraci, F. et al. TGF-beta1 pathway as a new target for neuroprotection in Alzheimer's disease. CNS Neurosci Ther 17, 237-249, doi:10.1111/j.1755-5949.2009.00115.x (2011).

36. Caraci, F. et al. A key role for TGF-beta1 in hippocampal synaptic plasticity and memory. Sci Rep 5, 11252, doi:10.1038/srep11252 (2015).

37. Chen, J. H., Ke, K. F., Lu, J. H., Qiu, Y. H. & Peng, Y. P. Protection of TGF-beta1 against neuroinflammation and neurodegeneration in Abeta1-42-induced Alzheimer's disease model rats. PLoS One 10, e0116549, doi:10.1371/journal.pone.0116549 (2015).

38. Caraci, F. et al. Dysfunction of TGF-beta1 signaling in Alzheimer's disease: perspectives for neuroprotection. Cell Tissue Res 347, 291-301, doi:10.1007/s00441-011-1230-6 (2012).

39. Caraci, F. et al. The CC genotype of transforming growth factor-beta1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression. Eur Neuropsychopharmacol 22, 281-289, doi:10.1016/j.euroneuro.2011.08.006 (2012).

40. Guo, L. et al. Targeting amyloid-beta in glaucoma treatment. Proc Natl Acad Sci U S A 104, 13444-13449, doi:10.1073/pnas.0703707104 (2007).

41. Dahlgren, K. N. et al. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277, 32046-32053, doi:10.1074/jbc.M201750200 (2002).

42. Lambert, M. P. et al. Vaccination with soluble Abeta oligomers generates toxicityneutralizing antibodies. J Neurochem 79, 595-605 (2001).

43. Barghorn, S. et al. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95, 834-847, doi:10.1111/j.1471-4159.2005.03407.x (2005).

44. Klein, W. L., Krafft, G. A. & Finch, C. E. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24, 219-224 (2001).

45. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408, doi:10.1006/meth.2001.1262 (2001).

46. Kutty, R. K. et al. MicroRNA expression in human retinal pigment epithelial (ARPE-19) cells: increased expression of microRNA-9 by N-(4-hydroxyphenyl)retinamide. Mol Vis 16, 1475-1486 (2010).

47. Lukiw, W. J., Surjyadipta, B., Dua, P. & Alexandrov, P. N. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease (AD) and in age-related macular degeneration (AMD). Int J Biochem Mol Biol 3, 105-116 (2012).

48. Ertekin, S. et al. Evaluation of circulating miRNAs in wet age-related macular degeneration. Mol Vis 20, 1057-1066 (2014).

49. Lin, H. et al. Effect of miR-23 on oxidant-induced injury in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 52, 6308-6314, doi:10.1167/iovs.10-6632 (2011).

50. Galimberti, D. et al. Circulating miRNAs as potential biomarkers in Alzheimer's disease. J Alzheimers Dis 42, 1261-1267, doi:10.3233/JAD-140756 (2014).

51. Lau, P. et al. Alteration of the microRNA network during the progression of Alzheimer's disease. EMBO Mol Med 5, 1613-1634, doi:10.1002/emmm.201201974 (2013).

52. Lugli, G. et al. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One 10, e0139233, doi:10.1371/journal.pone.0139233 (2015).

53. Haque, R. et al. MicroRNA-30b-mediated regulation of catalase expression in human ARPE-19 cells. PLoS One 7, e42542, doi:10.1371/journal.pone.0042542 (2012).

54. Schonrock, N. et al. Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta. PLoS One 5, e11070, doi:10.1371/journal.pone.0011070 (2010).

55. Hou, Q. et al. Inhibitory effect of microRNA-34a on retinal pigment epithelial cell proliferation and migration. Invest Ophthalmol Vis Sci 54, 6481-6488, doi:10.1167/iovs.13-11873 (2013).

56. Smit-McBride, Z. et al. Age-dependent increase in miRNA-34a expression in the posterior pole of the mouse eye. Mol Vis 20, 1569-1578 (2014).

57. Arora, A. et al. Prediction of microRNAs affecting mRNA expression during retinal development. BMC Dev Biol 10, 1, doi:10.1186/1471-213X-10-1 (2010).

58. Bai, Y. et al. MicroRNA-126 inhibits ischemia-induced retinal neovascularization via regulating angiogenic growth factors. Exp Mol Pathol 91, 471-477 doi:10.1016/j.yexmp.2011.04.016 (2011).

59. Sonntag, K. C., Woo, T. U. & Krichevsky, A. M. Converging miRNA functions in diverse brain disorders: a case for miR-124 and miR-126. Exp Neurol 235, 427-435, doi:10.1016/j.expneurol.2011.11.035 (2012).

60. Kutty, R. K. et al. Differential regulation of microRNA-146a and microRNA-146b-5p in human retinal pigment epithelial cells by interleukin-1beta, tumor necrosis factor-alpha, and interferon-gamma. Mol Vis 19, 737-750 (2013).

61. Zhuang, Z. et al. Down-regulation of microRNA-155 attenuates retinal neovascularization via the PI3K/Akt pathway. Mol Vis 21, 1173-1184 (2015).

62. Szemraj, M. et al. Serum MicroRNAs as Potential Biomarkers of AMD. Med Sci Monit 21, 2734-2742, doi:10.12659/MSM.893697 (2015).

63. Devlin, C., Greco, S., Martelli, F. & Ivan, M. miR-210: More than a silent player in hypoxia. IUBMB Life 63, 94-100, doi:10.1002/iub.427 (2011).

Tables

microRNA	Reference AMD	Reference AD
miR-9	46,47	databases
miR-21	48	databases
miR-23a	46,49	50,51
miR-24	48	52
miR-27a	28	29,30
miR-30b	53	54
miR-34a	55,56	databases
miR-125b	47,57	databases
miR-126	58	59
miR-146a	47,60	databases
miR-146b	60	databases
miR-155	61	31
miR-210	28,62,63	databases

Table 1: Selection of miRNAs potentially involved in AD and AMD. Databases: miR2Disease and Human microRNA Disease Database (HMDD).

microRNA	p-value miR-16	p-value snU6	FC miR-16	FC snU6
miR-9	0.059	0.051		
miR-21	0.29	0.081		
miR-23a	0.041	0.067		
miR-24	0.199	0.161		
miR-27a	0.046	0.012	2.47	2.75
miR-30b	0.94	0.957		
miR-34a	0.257	0.126		
miR-125b	0.45	0.604		
miR-126	0.597	0.657		
miR-146a	0.008	0.006	2.59	2.81
miR-146b	0.096	0.154		
miR-155	0.003	0.002	3.09	3.95
miR-210	0.364	0.917		

Table 2: Differential expression of miRNAs in retina obtained from rats injected with Aβ vs. control group

miRNA	p-value	FC
miR-9	0.006	6.47
miR-21	0.065	
miR-23a	0.006	2.11
miR-24	0.06	
miR-27a	0.004	4.13
miR-30b	0.274	
miR-34a	0.007	3.28
miR-125b	0.626	
miR-126	0.019	2.97
miR-146a	0.001	1.46
miR-146b	0.124	
miR-155	0.021	-5.09
miR-210	0.070	

Table 3: Fold-changes (FC) of miRNA expression in amd patients vs. control group (healthy subjects)

a. miR-27a, miR-146a, miR-155	p-value	#genes
TGF-beta signaling pathway	1.31E-11	44
Prion diseases	2.90E-11	14
Hippo signaling pathway	2.53E-07	60
AMPK signaling pathway	1.16E-06	62
Fatty acid biosynthesis	1.50E-06	3
Fatty acid elongation	7.45E-06	9
Lysine degradation	7.73E-06	22
Neurotrophin signaling pathway	8.25E-06	58
mTOR signaling pathway	2.61E-05	35
Protein processing in endoplasmic reticulum	2.65E-05	73
TNF signaling pathway	3.20E-05	51
Fatty acid metabolism	5.17E-05	16
Signaling pathways regulating pluripotency of stem cells	5.17E-05	62
FoxO signaling pathway	5.78E-05	60
Thyroid hormone signaling pathway	6.42E-05	48
Adherens junction	1.61E-04	36
Ubiquitin mediated proteolysis	3.12E-04	62
Central carbon metabolism in cancer	3.12E-04	30
HIF-1 signaling pathway	9.92E-04	51
ErbB signaling pathway	0.00238	39
Sphingolipid signaling pathway	0.00267	48
Focal adhesion	0.00326	81
Insulin signaling pathway	0.00431	58
NF-kappa B signaling pathway	0.00431	32
Apoptosis	0.00468	38
Cell cycle	0.00958	50
PI3K-Akt signaling pathway	0.01182	121
ECM-receptor interaction	0.01678	26
p53signaling pathway	0.02163	30
Toll-like receptor signaling pathway	0.02326	39
Axon guidance	0.03129	43
RNA transport	0.03376	62
Endocytosis	0.04531	72
b. miR-9, miR-23a, miR-27a, miR-34a, miR-126,miR-146a, miR-155	p-value	#genes
Fatty acid metabolism	3.15E+01	30
Fatty acid elongation	8.96E+03	14
Fatty acid degradation	2.02E+04	24
Adherens junction	3.86E+03	53
TGF-beta signaling pathway	4.74E+04	56
Fatty acid biosynthesis	8.23E+04	7
Thyroid hormone signaling pathway	9.39E+03	84
Protein processing in endoplasmic reticulum	9.39E+03	114
Prion diseases	1.09E+05	21
p53 signaling pathway	8.77E+05	54
mTOR signaling pathway	2.91E+06	47
Hippo signaling pathway	4.40E+06	90
Neurotrophin signaling pathway	5.23E+06	82
TNF signaling pathway	7.93E+05	74

	p-value	#genes
Cell cycle	0.000118	83
Endocytosis	0.000128	130
Signaling pathways regulating pluripotency of stem cells	0.000158	90
Sphingolipid signaling pathway	0.000427	76
ErbB signaling pathway	0.000524	62
Lysine degradation	0.000750	31
Axon guidance	0.000849	78
Estrogen signaling pathway	0.000868	63
Insulin signaling pathway	0.001037	91
Focal adhesion	0.001065	128
FoxO signaling pathway	0.001064	88
Ubiquitin mediated proteolysis	0.002076	89
HIF-1 signaling pathway	0.002212	72
Glycosaminoglycan biosynthesis - keratansulfate	0.002641	11
Regulation of actin cytoskeleton	0.004510	123
Apoptosis	0.005055	57
AMPK signaling pathway	0.007361	80
N-Glycan biosynthesis	0.014091	30
RNA degradation	0.024060	49
Fc gamma R-mediated phagocytosis	0.026970	55
NF-kappa B signaling pathway	0.026970	52
VEGF signaling pathway	0.030205	40
c. miR-155	**p-value**	**#genes**
TGF-beta signaling pathway	0.000469	11
FoxO signaling pathway	0.000469	26
Apoptosis	0.001294	20
Steroid biosynthesis	0.002126	4
NF-kappa B signaling pathway	0.002126	17
TNF signaling pathway	0.002137	22
Inflammatory bowel disease (IBD)	0.004661	13
Adherens junction	0.009666	14
Fatty acid elongation	0.011334	4
Signaling pathways regulating pluripotency of stem cells	0.011964	25

Table 4: KEGG pathways target of miRNAs potentially deregulated in AMD

Figure 1

Figure 2

Figure 3

Figure 4

Figure Legends

Figure 1: Box Plots of miRNAs in rat retina. Values on the y-axis are reported as $-\Delta Ct$. *$p < 0.05$, ** $p < 0.01$ vs. control.

Figure 2: Box Plots of miRNAs commonly dysregulated in AD and AMD patients. Values on the y-axis are reported as $-\Delta Ct$. *$p < 0.05$, ** $p < 0.01$ vs. control.

Figure 3: Scatter distribution of pathways regulated by miR-27a, miR-146a and miR-155. Solid spheres correspond to predicted pathways. Blue (dark gray in the print version) points are the projections of # of genes, red (gray in the print version) points are the projections # of microRNA, and green (light gray in the print version) points are the projections of p value associated to each pathway. (NT= neurotrophin signaling pathway, TNF= TNF signaling pathway, HIF= hypoxia inducible factor pathway).

Figure 4: Scatter distribution of pathways associated to miRNAs that are dysregulated in serum of AMD patients. Solid spheres correspond to predicted pathways. Blue (dark gray in the print version) points are the projections of # of genes, red (gray in the print version) points are the projections # of microRNA, and green (light gray in the print version) points are the projections of p value associated to each pathway. (NT= neurotrophin signaling pathway, TNF= TNF signaling pathway, HIF= hypoxia inducible factor pathway, VEGF= vascular endothelial growth factor).

DISCUSSION AND CONCLUSIONS

MiRNAs are small non-coding RNA sequences of about 22 nucleotides with a role as post-transcriptional regulators of gene expression. They impact many developmental and homeostatic processes. Moreover, significant changes of tissue miRNAs occur in various diseases, such as cancers, cardiovascular disease, nervous system disease. The findings on the presence of miRNAs in human fluids after the releasing from their cells of origin, numerous studies began to investigate tissue- and disease-specific miRNA signatures in blood, urine, spinal fluid or saliva. (72). MiRNAs have been shown to be protected by RNase digestion and are resistant to severe chemical-physical conditions. Accordingly, they result stable in plasma and serum.

Circulating miRNAs fulfil a number of criteria as ideal biomarkers for a variety of diseases: accessibility through non-invasive methods, high degree of specificity and sensitivity, ability to differentiate pathologies, long half-life within samples, rapid and accurate detection.

Therefore, serum or plasma miRNAs could represent a new approach for diagnostic minimally invasive screening. (63, 73, 74)

Characterization of differential expression patterns of miRNAs might be an approach for development of novel biomarkers in human diseases.
Moreover, a therapeutic approach aimed at dysregulated miRNA is promising. Once their role in the pathogenesis of human diseases will be identified, miRNAs could represent novel targets for drug development.

During my PhD program I evaluated miRNAs expression in retinal neurodegenerative diseases such as glaucoma and AMD, and tried to match with data from AD.

These three diseases display common features, such as amyloid and pTau aggregation, neuroinflammation, and oxidative damage. It is still unclear whether these similarities represent common initiating neurotoxic mechanisms or the downstream consequences of distinct insults. (75).

An early diagnosis to start effective therapy is necessary in order to stop the irreversible neurodegeneration process in glaucoma, AMD and AD.

The idea that neurodegenerative disease can be considered an RNA disorder (76), related to miRNA deregulation, is growing. Several studies showed significant changes in expression of some miRNAs in the brain of AD patients. We hypothesize that in glaucoma and AMD changes in miRNA expression could be similar to those reported in the brain of AD patients. Identification of deregulated miRNA and associated pathways common to glaucoma, AMD and AD might help in the developmet of biomarkers and new therapeutic strategies.

I looked at miRNA common to the three diseases by means of bioinformatic methods for prediction miRNAs. Prediction of involved miRNAs, allowed the identification of nine miRNAs deregulated in glaucoma, as well as in AD and AMD. Based on prediction of miRNA and associated biochemical pathways, I hypothesized that inflammation is one possible therapeutic target common to the three neurodegenerative diseases (glaucoma, AMD and AD).

Analysis of miRNAs in clinical trial revealed that 7 miRNAs were upregulated in serum of AMD patients in comparison to control group (miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 and miR-126). Three miRNAs have been also deregulated both in AMD patients and in retina of Aβ injected rats (miR-27a, miR-146a, miR-155).

My results are in accordance with previous studies that showed mir-146a and miR-155 dysregulated in AMD retina and identified them as regulators of inflammation and microglial activation state in response to stress. To my knowledge, dysregulation of miR-27a has not been reported yet, neither in experimental animal models nor in in vitro models of AMD.

I have found that miRNAs, deregulated both in serum of AMD patients and retina of Aβ injected rats, can regulate pathways associated to neurodegenerative diseases (e.g. apoptosis, ubiquitin proteolysis, neurotrophin signaling) along to inflammatory signaling pathways (e.g. mTOR, HIF, TNFα and VEGF signaling). Furthermore, TGF-β signaling has been one of the top scored pathways along with "prion diseases" pathway. Deregulation of TGF-β pathway in AD and protection of TGF-β1 toward brain neuroinflammatory process was previously reported and TGF-β1 administration reverted the Bax/Bcl2 ratio in retina of Aβ injected rats.

The present results suggest that miR-27a, miR-146a and miR-155 might be up-regulated due to Aβ deposition in drusen bodies, in the retina of AMD patients, leading to inflammatory and neurodegenerative events; the progression of AMD can be characterized by secretion of circulating miRNAs associated to Alzheimer's disease (miR-9, miR-23a, miR-27a, miR-34a, miR-126, miR-146a, miR-155) that regulate genes involved in neurodegenerative and inflammatory pathways.

In conclusion I suggest that miR-9, miR-23a, miR-27a, miR-34a, miR-146a, miR-155 could represent potential biomarkers and new pharmacological targets for AMD.
These findings support the execution of future studies in order to assess the role of specific miRNAs as potential biomarkers and therapeutic targets in neurodegenerative diseases.

REFERENCES

1. Madeira MH et al. Contribution of microglia-mediated neuroinflammation to retinal degenerative diseases. Mediators Inflamm. (2015) 2015:673090. doi: 10.1155/2015/673090. Epub 2015 Mar 22).

2. Kyoko Ohno-Matsui. Parallel findings in age-related macular degeneration and Alzheimer's disease. Progress in Retinal and Eye Research 30 (2011) 217e238

3. Gupta V et al. One protein, multiple pathologies: multifaceted involvement of amyloid β in neurodegenerative disorders of the brain and retina. Cell. Mol. Life Sci. (2016) 73:4279–4297

4. Gupta VK et al. Amyloid beta accumulation and Inner retinal degenerative changes in Alzheimer's disease transgenic mouse. Neurosci Lett (2016) 623:52–5.

5. Iseri PK et al. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol (2006) 26:18–24

6. Anderton, B.H. Changes in the ageing brain in health and disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (1997) 352, 1781e1792

7. Walsh, D.M., Selkoe, D.J. A beta oligomers - a decade of discovery. J. Neurochem. (2007) 101, 1172e1184

8. Kurji, K.H. et al. Microarray analysis identifies changes in inflammatory gene expression in response to amyloid-beta stimulation of cultured human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2010) 51, 1151e1163

9. Gupta V et al. BDNF impairment is associated with age-related changes in the inner retina and exacerbates experimental glaucoma. Biochim Biophys Acta (2014) 1842:1567–1578

10. Feeney-Burns L, Ellersieck MR. Age-related changes in the ultrastructure of Bruch's membrane. Am J Ophthalmol. (1985) 100:686–97.

11. Strauss O. The retinal pigment epithelium in visual function. Physiol Rev. (2005) 85:845–81. doi:10.1152/physrev.00021.2004

12. Curcio CA et al. Accumulation of cholesterol with age in human Bruch's membrane. Invest Ophthalmol Vis Sci. (2001) 42:265–74.

13. Delori F et al. Age-related accumulation and spatial distribution of lipofuscin in RPE of normal subjects. Invest Ophthalmol Vis Sci. (2001) 42:1855–66.

14. Eldred GE et al. Lipofuscin: resolution of discrepant fluorescence data. Science (New York, NY). (1982) 216:757–9

15. Moreira EF et al. 7-Ketocholesterol is present in lipid deposits in the primate retina: potential implication in the induction of VEGF and CNV formation. Invest Ophthalmol Vis Sci. (2009) 50:523–32. doi:10. 1167/iovs.08-2373

16. Mullins RF et al. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Faseb J. (2000) 14:835–46.

17. Russell SR et al. Location, substructure, and composition of basal laminar drusen compared with drusen associated with aging and age-related macular degeneration. Am J Ophthalmol. (2000) 129:205–14

18. Tan Perciliz L. et al. AMD and the alternative complement pathway: genetics and functional implications. Human Genomics. (2016) 10:23

19. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. (2008) 358:2606–17. doi:10.1056/NEJMra0801537.,

20. Davis MD et al. The Age-Related Eye Disease Study severity scale for agerelated macular degeneration: AREDS report no. 17. Arch Ophthal. (2005) 123: 1484–98. doi:10.1001/archopht.123.11.1484.

21. Ferris FL et al. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthal. (2005) 123:1570–4. doi:10.1001/archopht.123.11.1570

22. Mansour AM et al. Ziv-aflibercept in macular disease. Br J Ophthalmol. (2015) Aug;99(8):1055-9. doi: 10.1136/bjophthalmol-2014-306319

23. Solomon SD et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews (2014) Issue 8. [DOI: 10.1002/14651858.CD005139.pub3

24. Moja L et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database of Systematic Reviews (2014) Issue 9. [DOI: 10.1002/14651858.CD011230.pub2

25. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. British Journal of Ophthalmology (2008) 92(5):667–8

26. Holash J et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences of the United States of America (2002) 99(17): 11393–8

27. Lenworth N. Johnson. Glaucoma as a Neurodegenerative Disease: Why We Must 'Look for the Protein. RIMJ (2016)

28. Davis BM et al. Glaucoma: the retina and beyond Acta Neuropathol. (2016) Aug 20. [Epub ahead of print])

29. Kass MA et al. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypertensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 120:701-713.

30. Gordon MO et al. The Ocular Hypertension Treatment Study. Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 120:714-720.

31. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) 2. Results of argon laser trabeculoplasty versus topical medicines. Ophthalmology (1990) 97:1403-13.

32. Glaucoma Laser Trial Research Group. The Glaucoma Laser Trial (GLT) and Glaucoma Laser Trial Follow-up Study: 7. Results. Am J Ophthalmol (1995) 120:718-31

33. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraoc ular pressure and visual field deterioration. Am J Ophthalmol (2000) 130:429-440.

34. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. Am J Ophthalmol (2001) 132:311-320.

35. Lichter PR et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study (CIGTS) comparing initial treatment randomized to medications or surgery. Ophthalmology (2001) 108:1943-53

36. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol (1998) 126:487-97.

37. Heijl A et al.: Reduction of intraocular pressure and glaucoma progression. Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (2002) 120:1268-79

38. Qinghua Cui et al. MicroRNAs preferentially target the genes with high transcriptional regulation complexity. Biochemical and Biophysical Research Communications 352 (2007) 733–738

39. Ambros V, Horvitz HR. Heterochronic mutants of the nematode Caenorhabditis elegans. Science (1984) 226(4673):409-416

40. Lee RC et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 75(5):843-854

41. Kim V.N. MicroRNA biogenesis: coordinated cropping and dicing, Nat. Rev. Mol. Cell Biol. 6 (2005) 376–385

42. Cullen B.R.. Transcription and processing of human microRNA precursors, Mol. Cell 16 (2004) 861–865

43. Juan Wang et al. TransmiR: a transcription factor–microRNA regulation database. Nucleic Acids Research, (2010) Vol. 38, Database issue.

44. Carmell M.A., Hannon G.J. RNase III enzymes and the initiation of gene silencing, Nat. Struct. Mol. Biol. 11 (2004) 214–218

45. G. Meister, T. Tuschl, Mechanisms of gene silencing by doublestranded RNA, Nature 431 (2004) 343–349

46. Priyanka Shahi et al. Argonaute—a database for gene regulation by mammalian microRNAs. Nucleic Acids Research, (2006) Vol. 34, Database issue.

47. Tijsterman M. and Plasterk R.H. Dicers at RISC; the mechanism of RNAi. Cell, (2004) 117,551–3. 6

48. Tang G. siRNA and miRNA: an insight into RISCs. Trends Biochem. Sci., (2005) 30, 106–114

49. Griffiths-Jones S. et al. Rfam: annotating non-coding RNAs in complete genomes, Nucleic Acids Res. 33 (2005) D121–D124.

50. Berezikov E et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell (2005) 120:21–24

51. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 116(2):281-297

52. Jovanovic M, Hengartner MO. miRNAs and apoptosis: RNAs to die for. Oncogene (2006) 25(46):6176-6187

53. Ambros V. The functions of animal microRNAs. Nature 2004, 431(7006):350-355

54. Boehm M, Slack FJ. MicroRNA control of lifespan and metabolism. Cell Cycle (2006) 5(8):837-840

55. Li Y et al. MicroRNA-9a ensures the precise specification of sensory organ precursors in Drosophila. Genes & development (2006) 20(20):2793-2805

56. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 6(11):857-866

57. Zeng Y. Principles of micro-RNA production and maturation. Oncogene (2006) 25(46):6156-6162

58. Yiming Zhou et al. Inter- and intra-combinatorial regulation by transcription factors and microRNAs. BMC Genomics (2007) 8:396 doi:10.1186/1471-2164-8-396).

59. Manel Esteller. Molecular Origins of Cancer Epigenetics in Cancer. N Engl J Med (2008) 358:1148-59.

60. Chen C-Z. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med (2005) 353:1768-71.

61. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 6:857-66.

62. Lu J et al. MicroRNA expression profiles classify human cancers. Nature (2005) 435:834-8

63. Chen X et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. (2008) 18:997–1006].

64. Berber P et al. An Eye on Age-Related Macular Degeneration: The Role of MicroRNAs in Disease Pathology. Mol Diagn Ther. (2016) Sep 23. [Epub ahead of print]

65. Ryan, D.G. et al. MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. Mol. Vis (2006) 12, 1175–1184

66. Karali, M. et al. Identification and characterization of microRNAs expressed in the mouse eye. Invest. Ophthalmol. Vis. Sci. (2007) 48, 509–515

67. Carol J. et al. A common microRNA signature in mouse models of retinal degeneration. Experimental Eye Research 87 (2008) 529–534).

68. Alexandrov PN et al. Up-regulation of miRNA- 146a in progressive, age-related inflammatory neurodegenerative disorders of the human CNS. Front Neurol. (2014) 5:1–5

69. Chen, Y.; Gorski, D.H. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood (2008) 111, 1217–1226

70. Kuehbacher, A. et al. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol. Sci. (2008) 29, 12–15

71. Urbich, C. et a. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc. Res. (2008) 79, 581–588

72. Moldovan L et al. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. (2014);18(3):371-90. doi: 10.1111/jcmm.12236.

73. Gilad S et al. Serum microRNAs are promising novel biomarkers. PLoS One (2008); 3(9):e3148

74. Mitchell PS et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008); 105(30):10513-8

75. Sivak Jeremy M. The Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease. IOVS (2013) Vol. 54, No. 1

76. Johnson, R. et al. Neurodegeneration as an RNA disorder. Progress in Neurobiology. (2012) 99, 293-315

LIST OF PUBLICATIONS AND SCIENTIFIC CONTRIBUTIONS

- **Romano GL**, Platania CB, Forte S, Salomone S, Drago F, Bucolo C. MicroRNA target prediction in glaucoma. Prog Brain Res. 2015;220:217-40;

- **Romano GL** et al. Retinal miRNA expression on amyloid-β-induced age-related macular degeneration in rat: a translational study. Sci. Report. Submitted;

- Fisichella V, Giurdanella G, Platania CB, **Romano GL**, Leggio GM, Salomone S, Drago F, Caraci F, Bucolo C. TGF-β1 prevents rat retinal insult induced by amyloid-β (1-42) oligomers. Eur J Pharmacol. 2016 Sep 15;787:72-7. doi: 10.1016/j.ejphar.2016.02.002. PMID:26845696;

- Bucolo C, Musumeci M, Salomone S, **Romano GL**, Leggio GM, Gagliano C, Reibaldi M, Avitabile T, Uva MG, Musumeci S, Drago F. Effects of Topical Fucosyl-Lactose, a Milk Oligosaccharide, on Dry Eye Model: An Example of Nutraceutical Candidate. Front Pharmacol. 2015 Nov 18;6:280. doi: 10.3389/fphar.2015.00280. PMID:26635620;

- Platania CB, Di Paola L, Leggio GM, **Romano GL**, Drago F, Salomone S, Bucolo C. Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front Pharmacol. 2015 Oct 29;6:248. doi:;

- Pittalà V, Salerno L, Romeo G, Siracusa MA, Modica MN, **Romano GL**, Salomone S, Drago F, Bucolo C. Effects of novel hybrids of caffeic acid phenethyl ester and NSAIDs on experimental ocular inflammation. Eur J Pharmacol. 2015 Apr 5;752:78-83. doi:;10.1016/j.ejphar.2015.02.012.PMID:25704612;

- Leonardi A, Bucolo C, **Romano GL**, Platania CB, Drago F, Puglisi G, Pignatello R. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int J Pharm. 2014 Aug 15;470(1-2):133-40. doi: 10.1016/j.ijpharm.2014.04.061. PMID: 24792979;

- Bucolo C, Marrazzo G, Platania CB, **Romano GL**, Drago F, Salomone S. Effects of topical indomethacin, bromfenac and nepafenac on lipopolysaccharide-induced ocular inflammation. J Pharm Pharmacol. 2014 Jul;66(7):954-60. doi: 10.1111/jphp.12224. PMID: 24697218.

Conference procedeedings

- **<u>Romano GL</u>**, Bucolo C, Platania CB, Leggio GM, Salomone S, Drago F. Age-related degenerative disease: what we can learn from glaucoma. Seminario annuale per assegnisti e dottorandi della Società Italiana di Farmacologia (SIF). 16-18 settembre 2014- Rimini (ITA)

- **<u>Romano GL</u>**, Giurdanella G, Fisichella V, Leggio GM, Platania CB, Laudicina M, Salomone S, Caraci F, Bucolo C and Drago F. Neuroprotective effects of TGF-β1 in rat retinal β-amyloid-induced damage. 37° Congresso nazionale della Società Italiana di Farmacologia (SIF). 27-30 ottobre 2015 –Napoli (ITA)

- **<u>Romano GL</u>**, Bucolo C, Platania CB, Leggio GM, Salomone S, Drago F. Age-related degenerative disease: what we can learn from glaucoma. 27th European College of Neuro Psycopharmacology Congress (ECNP). 18-21 ottobre 2014 – Berlin (DE)

- **<u>Romano GL</u>**, Platania CB, Forte S, Salomone S, Drago F, Bucolo C. Common miRNAs in Alzheimer's disease and retinal degenerative diseases. The Association for Research in Vision and Ophtalmology meeting (ARVO), 3-7 maggio 2015- Denver (USA)

- **<u>Romano GL</u>**, Platania CB, Forte S, Salomone S, Drago F, Bucolo C. Common miRNAs in Alzheimer's disease and retinal degenerative diseases. 28th European College of Neuropsycopharmacology Congress (ECNP), 29 agosto-1 settembre 2015 – Amsterdam (NL)

- **<u>Romano GL</u>**, Bucolo C, Platania CB, Leggio GM, Salomone S, Drago F. Age-related degenerative disease: what we can learn from glaucoma. 12th Summer school of Neurosciences, 28 giugno – 4 luglio 2014 – Catania

- **<u>Romano GL</u>**, Platania CB, Forte S, Salomone S, Drago F, Bucolo C. Common miRNAs in Alzheimer's disease and retinal degenerative diseases. Seminario annuale per assegnisti e dottorandi della Società Italiana di Farmacologia (SIF), 16-18 settembre 2014 -Rimini

- **Romano GL**, Platania CB, Forte S, Salomone S, Drago F, Bucolo C. Common miRNAs in Alzheimer's disease and retinal degenerative diseases. 13th Summer school of Neurosciences, 11-17 luglio 2015 – Catania